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Background: The drainage, irrigation and fibrinolytic therapy (DRIFT) trial, conducted in 2003–6, showed
a reduced rate of death or severe disability at 2 years in the DRIFT compared with the standard treatment
group, among preterm infants with intraventricular haemorrhage (IVH) and post-haemorrhagic ventricular
dilatation.
Objectives: To compare cognitive function, visual and sensorimotor ability, emotional well-being, use of
specialist health/rehabilitative and educational services, neuroimaging, and economic costs and benefits at
school age.
Design: Ten-year follow-up of a randomised controlled trial.
Setting: Neonatal intensive care units (Bristol, Katowice, Glasgow and Bergen).
Participants: Fifty-two of the original 77 infants randomised.
Interventions: DRIFT or standard therapy (cerebrospinal fluid tapping).
Main outcome measures: Primary – cognitive disability. Secondary – vision; sensorimotor disability;
emotional/behavioural function; education; neurosurgical sequelae on magnetic resonance imaging;
preference-based measures of health-related quality of life; costs of neonatal treatment and of subsequent
health care in childhood; health and social care costs and impact on family at age 10 years; and a decision
analysis model to estimate the cost-effectiveness of DRIFT compared with standard treatment up to the
age of 18 years.
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Results: By 10 years of age, 12 children had died and 13 were either lost to follow-up or had declined to
participate. A total of 52 children were assessed at 10 years of age (DRIFT, n= 28; standard treatment, n= 24).
Imbalances in gender and birthweight favoured the standard treatment group. The unadjusted mean cognitive
quotient (CQ) score was 69.3 points [standard deviation (SD) 30.1 points] in the DRIFT group compared with
53.7 points (SD 35.7 points) in the standard treatment group, a difference of 15.7 points, 95% confidence
interval (CI) –2.9 to 34.2 points; p= 0.096. After adjusting for the prespecified covariates (gender, birthweight
and grade of IVH), this evidence strengthened: children who received DRIFT had a CQ advantage of 23.5 points
(p= 0.009). The binary outcome, alive without severe cognitive disability, gave strong evidence that DRIFT
improved cognition [unadjusted odds ratio (OR) 3.6 (95% CI 1.2 to 11.0; p= 0.026) and adjusted OR 10.0
(95% CI 2.1 to 46.7; p= 0.004)]; the number needed to treat was three. No significant differences were found
in any secondary outcomes. There was weak evidence that DRIFT reduced special school attendance (adjusted
OR 0.27, 95% CI 0.07 to 1.05; p= 0.059). The neonatal stay (unadjusted mean difference £6556, 95% CI
–£11,161 to £24,273) and subsequent hospital care (£3413, 95% CI –£12,408 to £19,234) costs were
higher in the DRIFT arm, but the wide CIs included zero. The decision analysis model indicated that DRIFT
has the potential to be cost-effective at 18 years of age. The incremental cost-effectiveness ratio (£15,621
per quality-adjusted life-year) was below the National Institute for Health and Care Excellence threshold.
The cost-effectiveness results were sensitive to adjustment for birthweight and gender.
Limitations: The main limitations are the sample size of the trial and that important characteristics were
unbalanced at baseline and at the 10-year follow-up. Although the analyses conducted here were
prespecified in the analysis plan, they had not been prespecified in the original trial registration.
Conclusions: DRIFT improves cognitive function when taking into account birthweight, grade of IVH and
gender. DRIFT is probably effective and, given the reduction in the need for special education, has the
potential to be cost-effective as well. A future UK multicentre trial is required to assess efficacy and safety
of DRIFT when delivered across multiple sites.
Trial registration: Current Controlled Trials ISRCTN80286058.
Funding: This project was funded by the NIHR Health Technology Assessment programme and will be
published in full in Health Technology Assessment; Vol. 23, No. 4. See the NIHR Journals Library website
for further project information. The DRIFT trial and 2-year follow-up was funded by Cerebra and the James
and Grace Anderson Trust.
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Plain English summary
B leeding into the fluid spaces of the brain is a common complication of being born very early. Suchbleeds often block the normal fluid flow around the brain, causing expansion of the fluid spaces
(ventricles), pressure on the brain and serious disability.
The standard treatment is to drain off excess fluid with a needle. This may need to be repeated and often
leads to further complications. An alternative treatment is to wash out the blood clot and clear the effects
of bleeding. This is called drainage, irrigation and fibrinolytic therapy (DRIFT).
Fifteen years ago (2003–6), the new DRIFT washout treatment was compared with standard treatment in a
randomised trial. A total of 77 premature babies with bleeding in, and expansion of, the brain spaces were
studied. At age 2 years, the babies in the washout (DRIFT) group were doing slightly better. Fewer of them
had severe learning problems than those in the standard treatment group.
In the present study, we followed up those babies we could trace to school age. We managed to examine
52 out of the 66 surviving babies.
DRIFT improved cognitive function and reduced the need for special education at age 10 years. This is the
first treatment to show improved brain function in premature babies with this condition.
DRIFT treatment was slightly more expensive. However, the long-term benefits were such that, after taking
into account the costs of special schooling, the treatment was probably cheaper overall.
Despite these results, it is not possible to implement DRIFT in the NHS right away. Few centres have the
skills and expertise to deliver DRIFT safely and, with improvements in survival of the most immature babies,
those who would be eligible for DRIFT are now even more premature than those included in the original
trial. Therefore, we recommend the development of DRIFT for the NHS through a further implementation
trial based in a few specialist centres.
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Scientific summary
Background
Severe intraventricular haemorrhage (IVH) with post-haemorrhagic ventricular dilatation (PHVD) is a serious
neurological complication seen in preterm infants, with significant neurodisability in survivors. No medical
intervention has been proven to reduce neurodevelopmental disability in infants with PHVD.
Objectives
Our primary hypothesis was that drainage, irrigation and fibrinolytic therapy (DRIFT) will reduce severe
cognitive disability in children assessed at school age.
Our secondary hypotheses were that DRIFT will:
l improve cerebral visual dysfunction
l improve sensorimotor ability
l improve education outcomes
l improve emotional/behavioural difficulties
l improve preference-based measures of health-related quality of life (HRQoL)
l reduce the health, social care and broader societal costs at 10-year follow-up.
The aims of this study were to:
1. compare cognitive function, visual function, sensorimotor ability and emotional well-being between
the two treatment groups in the DRIFT trial at school age
2. explore the use of specialist health/rehabilitative and educational services
3. estimate the economic cost and outcomes of the DRIFT intervention by age 11 years and model
longer-term costs and outcomes
4. assess ventricular dilatation and neurosurgical sequelae in the two treatment groups by clinical
neuroimaging.
Methods
Design
This was a long-term follow-up study of a multicentre randomised controlled trial set in neonatal intensive
care units in Bristol (UK), Katowice (Poland), Glasgow (UK) and Bergen (Norway).
Participants
The children, now aged 10 years, had been randomised to the DRIFT trial as preterm infants and all had
suffered a severe degree of PHVD. A small feasibility study preceded the follow-up study, in which all
assessments were tested for suitability in the children. The families and children assisted in designing the
follow-up study to suit their needs and requirements.
Sample size
In total, 77 children were randomised to the DRIFT trial during 2003–6, of whom 69 survived until age
2 years. Based on a similar effect size documented with severe cognitive disability at age 2 years, a
two-group continuity corrected chi-squared test with a 5% two-sided significance level had 80% power
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to detect the difference in severe cognitive disability between a control group proportion of 59% and an
odds ratio (OR) of 0.17 (i.e. an intervention proportion of 19.7%) when the sample size in each group is
28. With 60 infants (30 in each group), the power was 97% (with an alpha of 5%) to detect a mean
cognitive difference of one standard deviation (SD) (commonly 15 points) between the DRIFT and standard
treatment groups. It was anticipated that 45 UK children would be assessed in Bristol and 15 Polish children
in Katowice, assuming a 90% follow-up rate. Those from Bergen and Glasgow would be sought if numbers
were proving difficult to achieve.
Primary outcome
The primary outcome was cognitive disability at school age, expressed as a cognitive quotient (CQ).
The British Ability Scales version three was used for children with a developmental age of ≥ 3 years.
For children below this threshold, the Bayley Scales of Infant and Toddler Development version three
was administered. The final scores were in the format of a cognitive developmental quotient (0 to 100+).
Secondary outcomes
l Cerebral visual function: parent-reported visual ability and parent-completed cerebral visual impairment
(CVI) questionnaire.
l Sensorimotor disability: children were assessed using the Movement Assessment Battery for Children-2
(Movement ABC). Severity and numbers with cerebral palsy (CP) were also compared.
l Emotional/behavioural function: parent-completed Strengths and Difficulties Questionnaire (SDQ).
l Parent-reported education outcomes.
l Neurosurgical sequelae on structural brain magnetic resonance imaging (MRI).
l Preference-based measures of HRQoL: parents completed two generic measures of their child’s HRQoL
at 10-year follow-up, using the Health Utilities Index – 3 (HUI3) and the EuroQol-5 Dimensions,
five-level version (EQ-5D-5L).
l Costs of initial hospitalisation and treatment during the neonatal period (including emergency
transportation, periods of intensive care and readmissions based on hospital data in the Bristol cohort).
l Costs of subsequent health care in childhood (based on hospital data from the Bristol cohort).
l Health and social care costs and impact on family at 10-year follow-up (based on parent recall).
l Decision analysis model: a simple decision analytical model to estimate the cost-effectiveness of DRIFT
compared with standard care from birth to age 18 years. The primary perspective was that of NHS and
Personal Social Services in accordance with National Institute for Health and Care Excellence (NICE)
guidance. In secondary analysis, we broaden the perspective to include education costs.
Research ethics
Ethics approval was granted by the NHS Health Research Authority (14/SW/1078).
Results
Between September 2015 and April 2016 families were contacted and asked to take part in the 10-year
follow-up study. In two patients (two in DRIFT, zero in standard treatment), we were unable to find a
contact address or number. This left 67 patients where the survival status was known. Of these, there
were two deaths in the DRIFT arm and two deaths in the standard treatment arm, one patient declined
(in the standard treatment arm) and 10 gave no response, leaving 52 available for assessment: 28 in the
DRIFT arm and 24 in the standard treatment arm.
Among the 52 children available for follow-up assessments at 10 years, there were imbalances of gender and
birthweight favouring the standard treatment group. There were 22 males in the DRIFT arm (79%) whereas the
standard treatment arm had a lower proportion of males (63%). Birthweight was much higher in the standard
treatment arm (mean 1322 g) than in the DRIFT arm (1102 g). We prespecified in the analysis plan that any
baseline characteristics that differed by more than 10%/0.5 SDs would be adjusted for in a sensitivity analysis.
SCIENTIFIC SUMMARY
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Cognitive disability
Given the larger than expected attrition rate, precision was lower than hoped and was exacerbated further
by large SDs for the cognitive ability quotient. Despite this, results are in parallel with those at 2 years, with
crude estimates giving weak evidence that the DRIFT intervention increases cognitive ability at 10 years
(p = 0.096). After adjusting for the prespecified covariates of gender, birthweight and grade of IVH, this
evidence was strengthened and indicated that children who were in the DRIFT arm of the trial, on average,
had a CQ score of 23.5 points higher than those who received standard treatment (p = 0.009). This translates
into a developmental cognitive advantage of 2.5 years.
Sensitivity analysis for primary outcome
The binary outcome, alive without severe cognitive disability, gave very similar results to the continuous CQ
outcome [unadjusted OR 3.6, 95% confidence interval (CI) 1.2 to 11.0; p = 0.026 and adjusted OR 10.0,
95% CI 2.1 to 46.7; p = 0.004]. Both the unadjusted and adjusted model gave strong evidence to suggest
that DRIFT had a positive impact on children’s cognitive outcomes at 10 years. The number needed to treat
was three.
Vision
Overall, the results show that those in the DRIFT arm were almost four times more likely to have a ‘good’
visual outcome than the standard treatment arm (adjusted OR 3.73); however, the p-value shows only very
weak evidence to support this (p = 0.136). No difference was found in CVI mean score (–0.12, 95% CI
–0.47 to 0.24; p = 0.502).
Sensorimotor disability
There was no difference in mean Movement ABC scores (–1.0, 95% CI –16.8 to 14.8; p = 0.896). Children
in the DRIFT arm were 1.1 times more likely to have CP than those in the standard treatment arm (OR
1.10, 95% CI 0.36 to 3.35; p = 0.862). After adjustment for gender, birthweight and grade of IVH, this
changed to 63% lower odds of CP in the DRIFT group (OR 0.37, 95% CI 0.07 to 2.00; p = 0.249); this is
largely due to those in the DRIFT having less favourable baseline characteristics. Although the percentage
of children with CP was higher in the DRIFT arm than in the standard treatment arm (61% vs. 58%,
respectively), those in the DRIFT arm were less likely to have CP categorised as severe. After adjustment,
those in the DRIFT arm were 32% more likely to be ambulant than those in the standard treatment arm
(1.32, 95% CI 0.24 to 7.25; p = 0.751). However, given the large CI and p-value, the evidence to support
this finding was not strong; the result could have simply happened by chance.
Emotional/behavioural function
There was no difference in mean SDQ score (p = 0.584).
Neuroimaging
There were no major differences relating to residual neurosurgical conditions needing referral. Residual catheter
tracks were more often seen in the standard treatment group and in association with ventricular reservoirs.
Education outcomes
After adjustment, those in the DRIFT arm had lower odds (0.27) of special school attendance in the last
12 months than those in the standard treatment arm (p = 0.059).
Harms
Despite the excess secondary haemorrhages in the DRIFT group, the primary outcomes were better and
the secondary outcomes were no worse than in the standard treatment group. It does not appear that
secondary haemorrhages that occurred during the DRIFT procedure had a long-term detrimental effect.
High-resolution structural brain MRI at 10 years showed no evidence of damage associated with insertion
of the DRIFT irrigation catheters. There was no difference in ongoing neurosurgical problems between the
treatment arms at age 10 years.
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Cost of initial hospitalisation
Participants allocated to DRIFT had irrigation therapy for an average of 5.2 days at an estimated cost of
£1513 per participant. Some of this initial cost of DRIFT was offset by the fact that fewer patients had
reservoir procedures during the neonatal stay. The total mean costs of the neonatal stay were higher in
patients who had DRIFT, but the CI was wide and included zero (unadjusted mean difference £6556,
95% CI –£11,161 to £24,273). The finding was sensitive to adjustment for covariates, particularly
birthweight. After adjustment for birthweight, gender and IVH grade, estimated mean costs of neonatal
care were lower in patients who had DRIFT although CIs were still wide and included zero (adjusted mean
difference –£3056, 95% CI –£19,449 to £13,335).
Postnatal hospital admissions and total NHS secondary care costs
Participants allocated to DRIFT spent an average of 19.4 additional days in hospital up to age 2 years and an
average of 26.6 additional days in hospital between age 2 years and 31 March 2016. Participants allocated
to standard care spent fewer additional days in hospital (8.8 days at age 0–2 years; 18.5 days at age 2 years
upwards). The unadjusted total costs of hospital care after the initial neonatal stay were higher in participants
allocated to DRIFT (unadjusted mean difference £3413, 95% CI £12,408 to £19,234). This finding was very
sensitive to adjustment for covariates, particularly gender and birthweight. After adjustment, the estimated
mean cost among participants allocated to DRIFT was lower (adjusted mean difference –£9739, 95% CI
–£27,558 to £8080).
Use of ambulatory health and social care at ten-year follow-up
There was little evidence of a difference in emergency and outpatient care in the last 12 months at 10-year
follow-up. Participants in both arms of the trial reported an average of just over 0.4 visits to the emergency
department and just over 2.8 outpatient clinic visits. The adjusted mean difference in costs was marginally
higher in participants allocated to DRIFT (adjusted mean difference £2, 95% CI –£264 to £267). The costs
of other ambulatory care during the last 6 months were higher in participants randomised to standard care
(adjusted mean difference –£108, 95% CI –£596 to £380) but the CI was wide.
Family income, expenses and child’s educational needs
Overall, a similar proportion of parents/carers were employed at the 10-year follow-up. However, a lower
proportion of households of participants who received DRIFT had benefits as their main source of income
(adjusted OR 0.23, 95% CI 0.04 to 1.22), although the CI included 1. A higher percentage of parents of
participants in the standard treatment arm reported that their child attended a special unit or special
school (adjusted OR 0.13, 95% CI 0.02 to 0.82). Owing to the high cost of special schooling, this is
potentially economically important; the adjusted mean difference in estimated annual school costs was
–£5321, 95% CI –£9772 to –£870.
Health-related quality of life
In adjusted analyses, both the EQ-5D-5L and HUI3 scores of HRQoL tended to be higher in survivors who
were allocated to DRIFT than in those who were allocated to standard care. However, the CIs around the
adjusted mean differences in EQ-5D-5L score (0.06, 95% CI –0.11 to 0.22) and HUI3 score (0.13, 95% CI
–0.09 to 0.35) included zero.
Decision analytical model
DRIFT has the potential to be a cost-effective intervention at current NICE thresholds. Exploratory analysis
using a simulation model to interpolate and extrapolate costs and outcomes to age 18 years indicated that
the additional benefit [8.96 quality-adjusted life-years (QALYs) vs. 8.33 QALYs] in the DRIFT arm justifies
the higher NHS and social service costs (£112,341 vs. £102,611). The incremental cost-effectiveness ratio
(£15,621) was below the NICE thresholds of £20,000 to £30,000 per QALY and the incremental net
monetary benefit (£2711) was positive. When education costs are included or using costs and utility scores
adjusting for gender, IVH grade and birthweight, DRIFT has the potential to both save money and improve
outcomes for children.
SCIENTIFIC SUMMARY
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Conclusions
Implications for health care
The school-age follow-up of the DRIFT trial strengthens the evidence of benefit found at 2 years and adds
further evidence of safety of the intervention. We can conclude that DRIFT improves cognitive function
when taking into account birthweight, IVH grade and gender. The cost of the intervention is moderate;
DRIFT has the potential to be cost-effective. In some scenarios, DRIFT may save money and improve
outcomes owing to the possible reduction in the need for special education.
Recommendations for research
The role of any NHS implementation of DRIFT, ideally in a few specialised tertiary centres, delivered
through the existing neonatal operational delivery networks, will need to be studied prospectively in a
multicentre trial. As well as measures of cognition and functional measures, the data from the 10-year
outcomes indicate that any future studies should continue to collect data on vision, motor skills and
education, given the trends seen in the secondary outcomes that the study was not powered to address.
A larger proportion of infants with PHVD is now extremely immature. Further refinements in DRIFT may
need to be studied in this very immature group of patients.
For infants with parenchymal infarction in addition to PHVD, there is scope to supplement DRIFT with
novel interventions to promote brain tissue repair in the future.
Trial registration
This trial is registered as ISRCTN80286058.
Funding
Funding for the 10-year follow-up study was provided by the Health Technology Assessment programme
of the National Institute for Health Research. The DRIFT trial and 2-year follow-up was funded by Cerebra
and the James and Grace Anderson Trust.
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Chapter 1 Introduction
Scientific background
Haemorrhage into the ventricles of the brain is one of the most serious complications of preterm birth,
despite improvements in the survival of preterm infants. Large intraventricular haemorrhage (IVH) carries
a high risk of neurological disability and, by causing a progressive obliterative arachnoiditis at the basal
cisterns and the outlet foramina of the fourth ventricle, disturbs the flow and absorption of cerebrospinal
fluid (CSF).1 This leads to post-haemorrhagic ventricular dilatation (PHVD).
Severe IVH with PHVD is a neurological complication seen in preterm infants, with significant neurodisability in
survivors. Infants most at risk (those born at < 32 weeks of gestation and with a birthweight of < 1500 g) have
high rates of grade 3 or 4 IVH (around 6%), estimating approximately 800–900 new cases of grade 3 and 4 IVH
annually in the UK.2 Preterm birth rates are rising3 and survival rates of extremely preterm infants continue to
improve;4 therefore, it can be projected that the number of infants affected by PHVD will increase in the future.
In the US National Institute of Child Health and Development Neonatal Network, one-third of infants with
birthweights of < 1000 g develop IVH, and, of those, about 10% require implantation of a ventriculoperitoneal
(VP) shunt for PHVD.5 In a European study,6 29% of all preterm infants with severe IVH required implantation
of a VP shunt.
Of children with PHVD, 40% will develop cerebral palsy (CP) and approximately 25% will have multiple
disabilities. The National Institute of Child Health and Development study,5 the largest of its kind, studied
> 1000 preterm infants at 18–22 months corrected age with severe grade IVH (grade 3 and 4), of whom
almost 25% had PHVD (defined as requirement for a VP shunt). They demonstrated significant risk of
cognitive impairment with PHVD with a median Mental Development Index (MDI) score 20 points lower in
children with PHVD than in those with severe grade IVH without PHVD. The median MDI in children with
grade 3 IVH and PHVD was 61 points, and in those with grade 4 IVH and PHVD it was 50 points. Overall,
68% of children with severe grade IVH and PHVD had moderate cognitive impairment [MDI below two
standard deviations (SDs)] and 41% had severe cognitive impairment (MDI below three SDs). Furthermore,
70% of children with PHVD had CP and 30% had visual impairment. The presence of a haemorrhagic
parenchymal infarction, in addition to PHVD, increased the risk of CP to between 80% and 90%.5 A logistic
regression analysis7 of factors affecting school performance at 14 years of age in a cohort of 278 preterm
infants showed that peri- or intra-ventricular haemorrhage was the primary risk factor for special education.
Intraventricular blood and ventricular expansion have adverse effects on the immature periventricular white
matter by a variety of mechanisms including physical distortion, raised intracranial pressure,8 free radical
generation facilitated by free iron9 and inflammation.10
The prevalence of visual defects is higher among prematurely born children than children born at term11
and, in particular, the spectrum of vision problems known collectively as ‘cerebral visual impairment’ (CVI) is
a recognised complication of preterm brain injury, particularly if involving the periventricular white matter.12
Visual functions correlate with neurodevelopmental outcome and brain volume in preterm infants.13 Severe
CVI is the leading cause for children being registered as blind in the UK14 and the developed world and
may additionally be associated with ocular, optic nerve or refractive problems that cause further impairment.
Less severe CVI can damage visual skills and have an important effect on school performance and tasks of
everyday life.15 Clinical assessment of CVI is difficult before the age of 5 years; however, a recent study16
found evidence of CVI in 89% of children with known central nervous system damage.
Every preterm infant with severe CP or severe cognitive or visual impairment will require lifelong parental
and social care. The cost to society resulting from the complications of prematurity is significant. Based on
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2003 US figures,17 the estimated lifetime costs per infant with CP, severe cognitive impairment or blindness
is £614,000, £675,000 and £400,000, respectively. Data from the UK EPICure study18 indicate that, by
11 years of age, the annual health and social service costs of children with serious neurodevelopmental
disability are almost double those of children without disability (£1225 vs. £695, respectively). This adds a
significant additional economic burden on the NHS and social care. This estimate excludes the substantial
economic burden on parents/carers, special educational services and other public funds. A recent confidential
inquiry into premature death in adults with learning disabilities in England highlighted the complex lifelong
health and social care needs of individuals with learning disabilities. On average, each person with learning
difficulties had five additional medical conditions and received seven prescription medications; 64% of
individuals lived in residential care homes, the majority with 24-hour paid-nursing care.19
Reducing the rate of VP shunt insertion has been an important long-term objective in the management
of IVH and PHVD. The large amount of blood and protein in the CSF combined with the small size and
instability of the patient makes early VP shunt surgery impossible. Shunt implantation at the generally
accepted weight threshold of 2 kg, usually around term age, is still associated with a higher infection and
malfunction rate.20,21 Unfortunately, several interventions have failed to reduce the need for shunt insertion,
and no intervention has reduced neurodisability rates as a result of PHVD. Repeated lumbar punctures (LPs)
are often ineffective at allowing removal of enough CSF. Direct ventricular puncture through the anterior
fontanelle leads to needle track damage through the brain parenchyma. Repeated LPs or ventricular taps do
not reduce the risk that a shunt will eventually be required; they have no effect on neuromotor impairment
and are associated with a significant risk of ventriculitis (at 7% in the Ventriculomegaly Trial22–24).
In an effort to control PHVD by reducing CSF production, the International PHVD Drug Trial Group25
investigated the effects of acetazolamide and frusemide in a randomised trial in 1998. Not only did these
drugs not lead to an improvement in neuromotor development or CSF diversion requirements, but the
data monitoring committee stopped the trial because of worse outcome in the treated group.
In practice, once two LPs or one ventricular tap have been necessary to control the ventricular dilatation,
insertion of a ventricular reservoir is preferred. A reservoir provides an easy and safe route for repeated
aspiration of ventricular CSF, with low infection rates.6,26 Insertion requires an anaesthetic in a neurosurgical
theatre and can be safely performed in babies weighing < 800 g. This is a temporary measure and allows
repeated drainage of CSF until the need for permanent CSF diversion can be established through VP shunt
insertion. The most commonly encountered risks after reservoir insertion are infection and malfunction.6,26
The timing of insertion of a ventricular reservoir remains controversial. In a retrospective study,27 early
insertion, before crossing the 97th + 4 mm ventricular index line, was associated with lower rates of VP
shunt insertion. The Early vs Late Ventricular Intervention Study (ELVIS; ISRCTN43171322)28 randomised
between the two treatment thresholds, with death or shunt dependence and disability at 2 years being the
main treatment outcomes. The trial has ended but results are as yet not published. Endoscopic lavage is a
new neurosurgical intervention used for PHVD in which the ventricles are washed out under direct vision
using a small endoscope. A small feasibility study29 using historical controls seemed promising in terms of
safety and reducing the need for VP shunt insertion. Long-term outcomes are not known and the research
group concluded that this intervention needs to be tested objectively in a randomised controlled trial (RCT).
In summary, no medical or surgical intervention for PHVD has objectively demonstrated either a reduction
in the need for a permanent VP shunt or a reduction in death or neurodisability. Current practice in the
UK consists of repeated LPs followed by insertion of a ventricular reservoir to enable regular tapping to
reduce pressure. The complications are a combined infection and device failure rate exceeding 10%,
as highlighted above.
Drainage, irrigation and fibrinolytic therapy (DRIFT)30–32 is a surgical approach that was developed because
of the unsatisfactory results of other treatments. The objectives are to reduce pressure and distortion early
and to remove proinflammatory cytokines and free iron from within the ventricles. The procedure involves
INTRODUCTION
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insertion of right frontal and left occipital ventricular catheters under anaesthesia. Tissue plasminogen
activator (TPA), a fibrinolytic, is injected intraventricularly at a dose that is insufficient to produce a systemic
effect and this is left for approximately 8 hours. Under continuous intracranial pressure monitoring, the
ventricles are irrigated by artificial CSF through the frontal catheter. The occipital ventricular catheter is
simultaneously connected to a sterile closed ventricular drainage system and the height of the drainage
reservoir adjusted to increase or decrease drainage to maintain an intracranial pressure below 7 mmHg and
a net loss of 60–100 ml of CSF per day. The drainage fluid initially looks like cola but gradually clears, at
which point irrigation is stopped and the catheters removed. This commonly takes 72 hours but can take
up to 7 days.
After initial feasibility testing showed that DRIFT was technically possible and promising,30 the DRIFT
randomised trial started recruiting in 2003. Babies were elegible for the study if they were born preterm,
they had had IVH and their cerebral ventricles had expanded over predetermined limits. With parental
consent, 77 babies were randomised in Bristol, Katowice (Poland), Glasgow or Bergen (Norway) to either
DRIFT or standard therapy, which consisted of non-surgical conventional management (LPs to control
excessive expansion and pressure symptoms). If repeated LPs were needed, a ventricular reservoir was
surgically inserted to facilitate tapping CSF.
There were no differences in the short-term outcomes: need for VP shunt or death at 6 months.33 At
2 years post term, severe disability or death was significantly reduced in the DRIFT group.32 There was an
important decrease in severe cognitive disability (Bayley MDI three SDs below the mean) from 59% to
31% [adjusted odds ratio (OR) 0.17, 95% confidence interval (CI) 0.05 to 0.57] and the difference in
median MDI was > 18 points. Sensorimotor disability remained substantial in both treatment groups at
2 years: overall, 48% were unable to walk, 20% were unable to communicate and 9% had no useful
vision. Severe sensorimotor disability was less common in the DRIFT group but without reaching
statistical significance.
Although short-term neurodevelopmental measures are essential in the initial management of perinatal
interventions, longer-term measures provide far greater validity in assessing long-term functioning (and the
medical, societal and financial implications of these). Therefore, the main objective of the follow-up study
of the DRIFT trial was to assess if the cognitive advantage seen at 2 years with DRIFT continued through to
school age. Secondary objectives were to assess the long-term visual and motor function, emotional and
behavioural difficulties, brain structure and quality of life (QoL) as well as the cost-effectiveness of DRIFT.
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Chapter 2 Trial design and methods
Trial design
The DRIFT study was originally conducted in 2003–6 as a multicentre RCT that recruited premature infants
with PHVD. Infants were randomised to receive standard treatment or surgical DRIFT. Now, 10 years on,
the children have been followed up to investigate the difference in cognitive ability at school age between
the two groups.
The school-age follow-up of the DRIFT trial was designed in partnership with the children and parents who
attended a small feasibility study in Bristol. Families gave their input into the methods for initial contact,
parent and participant literature, feedback on the study assessments and the timing of the assessments so as
to not distract from school attendance. These families gave valuable advice on how to make the assessment
day engaging for the children. Mr Steven Walker-Cox and his son, who have lived experience of prematurity
and DRIFT, helped to write the letter of invitation, study materials and information leaflets and consent/
assent forms for parents and children. They also contributed to the research ethics application.
Research ethics approval (14/SW/1078) was granted by the National Research Ethics Service Committee
South West-Central Bristol prior to commencing the school-age follow-up. The University of Bristol acted
as sponsor.
Participants
Children previously enrolled in, and randomised to, the DRIFT trial between 2003 and 2006 were from
Bristol, Katowice, Glasgow or Bergen.
Children were eligible for the DRIFT trial if they matched all of the following criteria:
l IVH documented on ultrasonography.
l Age of no more than 28 days.
l Progressive dilatation of both lateral ventricles with each side:
¢ ventricular width 4 mm over the 97th centile (a)
OR
¢ anterior horn diagonal width 4 mm (1 mm over 97th centile) (b)
¢ thalamo-occipital distance 26 mm (1 mm over 97th centile) (c)
¢ third ventricle width 3 mm (1 mm over 97th centile) (d)
OR
¢ measurements above (a) or (b–d) on one side combined with obvious midline shift indicating a
pressure effect.
Exclusion criteria were:
l prothrombin time of > 20 seconds
OR
l accelerated partial thromboplastin time of > 50 seconds or a platelets count of < 50,000/µl.
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Interventions
DRIFT was developed as a surgical approach for reducing iron and proinflammatory cytokines from CSF
and reducing pressure and distortion early. The procedure involves insertion of right frontal and left
occipital ventricular catheters under anaesthesia. TPA, a fibrinolytic, is injected intraventricularly at a dose
that is insufficient to produce a systemic effect and this is left for approximately 8 hours. Under continuous
intracranial pressure monitoring, the ventricles are irrigated by artificial CSF through the frontal catheter.
The occipital ventricular catheter is simultaneously connected to a sterile closed ventricular drainage
system and the height of the drainage reservoir adjusted to increase or decrease drainage to maintain an
intracranial pressure below 7 mmHg and a net loss of 60–100 ml of CSF per day. The drainage fluid initially
looks like cola but gradually clears, at which point irrigation is stopped and the catheters removed. This
commonly takes 72 hours but can take up to 7 days.
Standard treatment consisted of up to two LPs to drain CSF followed by insertion of a ventricular reservoir
with regular tapping of CSF to reduce ventricular distension to within the specified dimensions.
Primary outcome
Cognitive disability at school age
Cognitive assessments were undertaken by child psychologists. The British Ability Scales version three
(BAS III)34 (see Appendices 1 and 2) was used for children with a developmental age of ≥ 3 years. For
children who did not meet this threshold, the Bayley Scales of Infant and Toddler Development (BSID III)35
(see Appendix 3) was administered. The final scores were in the format of a cognitive developmental
quotient (0 to 100+). The primary analysis was based on the cognitive scores of surviving children, although
a sensitivity analysis that included children who died (as a result of their disability) was also carried out,
in which the cognitive development quotient for these children could reasonably be assumed to be zero.
Secondary outcomes
Cerebral visual function
For the main visual outcomes, we used parent-reported data as they were available for the majority and
could be compared with the 2-year outcomes. Parents were asked whether their child had vision that was
of ‘No concerns’, ‘Normal with Correction’ or ‘Useful but not fully correctable’ or was ‘Blind or perceives
light only’. A binary outcome was created that split these into a good visual outcome (no concerns/normal
with correction) or a poor visual outcome (useful but not fully correctable/blind or perceives light only).
A 23-question assessment of CVI was also carried out by the vision specialists36 (see Appendix 4). A mean
score was created from all available questions and analysed between the groups. In the case of those who
attended assessments in Bristol, vision specialists directly assessed a range of visual functions including
visual acuity, visual field, eye movements and vision processing skills.
Sensorimotor disability
Assessments of motor function and disability were made by a paediatric physiotherapist. Children were
assessed using the Movement Assessment Battery for Children-2 (Movement ABC)37 (see Appendix 5).
As well as this assessment, the number and severity of CP were also compared between the two groups.
Emotional/behavioural function
Parents were asked to fill out the Strengths and Difficulties Questionnaire (SDQ)38 (see Appendix 6), which
assesses how their child behaves in various circumstances; their final score classifies them as having
‘normal behaviour’ or ‘abnormal behaviour’.
TRIAL DESIGN AND METHODS
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Methods
Sample size
In total, 77 children (54 from Bristol and 20 from Poland, two in Glasgow and one in Bergen) were randomised
to the DRIFT trial during 2003–6, of whom, 69 survived until the age of 2 years. Based on a similar effect size
documented with severe cognitive disability at age 2 years, a two-group continuity-corrected chi-squared test
with a 5% two-sided significance level would have 80% power to detect the difference in severe cognitive
disability between a control group proportion of 59% and OR of 0.17 (i.e. an intervention proportion of
19.7%) when the sample size in each group is 28. With 60 infants (30 in each group), we would have 97%
power (with an alpha of 5%) to detect a mean cognitive difference of one SD (commonly 15 points) between
the DRIFT and control groups.
It was anticipated that 45 UK children would be assessed in Bristol and 15 Polish children in Katowice,
assuming a 90% follow-up rate. Those from Bergen and Glasgow would be sought if numbers were
proving difficult to obtain.
Randomisation
A computer-generated randomisation scheme was used to assign infants to treatment groups in a
1 : 1 ratio.31 Given that the trial was taking place in four different centres, the randomisation process was
stratified by centre in blocks of eight, 10 or 12. Each infant was allocated to treatment using sequentially
numbered, doubled-up envelopes that each contained either a ‘DRIFT’ or ‘standard treatment’ card.
Envelope preparation and random number allocation were carried out using StatsDirect software
(StatsDirect, Altrincham, UK) by a research assistant not involved in enrolment or treatment. Patients were
enrolled by one of the neonatologist investigators, all of whom, at that stage, were blind to treatment
allocation. When the informed consent process was completed and signed, the next trial envelope was
opened and treatment allocation confirmed.
Blinding
Owing to the nature of the intervention delivery, once the envelope had been opened, it was not possible
to blind practices/parents to their allocation to either DRIFT or standard treatment. At 10 years, all
investigators (child psychologists, visual specialists, etc.) were blinded to treatment allocation and grade of
IVH as these were not apparent. All analysts (statisticians/health economists) were blinded to treatment
allocation as far as possible. Given that the results were published at 2 years in favour of the DRIFT arm,
it could be argued that the statisticians could have easily assumed which group was which. However, they
continued the analysis with groups A and B, and only the senior statistician was shown the allocation in
order for a draft abstract to be written (February 2016). As soon as the deaths were analysed in April 2016,
the statistician felt that she could no longer be classed as ‘blinded’.
Statistical methods
The main statistical analyses were prespecified using a statistical analysis plan (SAP) and the health
economics using a health economics analysis plan. The final version of the SAP was accepted and agreed
on 6 April 2016. Although a short interim analysis was completed in February 2016 on children assessed
up to that point, no major changes were made to the SAP after this time. Given the large differences seen
between the two groups at 2 years, it was difficult for the statistician to remain blinded. Final data analysis
started on 6 April 2016 and finished in October 2016. Stata® 14.1 (StataCorp LP, College Station, TX, USA)
was used for all statistical and health economic analyses in this trial. Binary outcomes were presented as
n (%) while continuous outcomes were presented as mean (SD)/median [interquartile range (IQR)], as
appropriate. For secondary and subgroup analyses, emphasis was placed more on descriptive statistics than
on p-values. An informal Bonferroni technique was applied when interpreting p-values; alpha divided by
four secondary and seven subgroup analyses: 0.05 ÷ 11= 0.0045. The p-values for exploratory outcomes
were interpreted with extreme caution.
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Primary analysis
Cognitive assessments were undertaken by child psychologists. The BAS III (see Appendices 1 and 2) was
used for children with a developmental age of ≥ 3 years. For children who did not meet this threshold, the
BSID III (see Appendix 3) was administered. The final scores were in the format of a cognitive developmental
quotient; therefore, a continuous variable. The primary analysis was conducted using the intention-to-treat
(ITT) principle using linear regression. The DRIFT team had determined, a priori, the variables that they
believed might confound the final result. Compatible with the previous investigation at 2 years, adjustments
were made for grade of IVH, birthweight and gender.
Null hypothesis: the average score for cognitive disability is the same for both groups.
Alternative hypothesis: the average score for cognitive disability is different between the groups.
As stated in the protocol, we were also interested in the proportion of children alive and without severe
cognitive disability (BAS III score of < 3 SDs for age) at 10 years compared with those with severe disability
or who had died owing to disability. To avoid splitting the 5% alpha between two primary outcomes, it
was added as a sensitivity analysis.
The primary hypothesis was that neurosurgical DRIFT would reduce severe cognitive impairement in
children assessed at school age. This was measured using cognitive ability tests. At 10 years children were
assessed using the BSID III (for those anticipated to be performing at below the 3 years level), BAS III early
years (for those anticipated to be performing between the 3 years and 7 years levels) or BAS III school age
scoring system (for the remainder).
A quotient score was generated in the following way:
1. Cognitive and language developmental age-equivalent (DAE) scores yielded from the BSID III were
collected and averaged to produce an overall DAE.
2. DAE scores from the BAS III early years assessment were averaged across the core scales (verbal
comprehension, picture similarities, naming vocabulary, pattern construction, matrices and copying)
to produce an overall DAE. DAE scores of ‘less than 3′ were given an age of 2 years and 11 months.
3. DAE scores from the BAS III school age assessment were averaged across the core scales (recognition of
designs, word definitions, pattern construction, matrices, verbal similarities and quantitative reasoning)
to produce an overall DAE. DAE scores of ‘less than 5′ were given an age of 4 years and 11 months.
4. All DAE scores were then divided by the child’s actual age and then multiplied by 100 to achieve the
child’s ‘Cognitive Quotient Score’.
Secondary analysis
Visual assessment
Visual assessments consisted of parent-reported outcomes and assessments carried out by vision specialists.
The main visual outcome was parent reported, as used at 2 years. For the main visual outcomes, parents
were asked whether their child had vision that was of ‘No concerns’, ‘Normal with correction’ or ‘Useful
but not fully correctable’ or was ‘Blind or perceives light only’. A binary outcome was created that split
these into a good visual outcome (no concerns/normal with correction) or a poor visual outcome (useful
but not fully correctable/blind or perceives light only). Differences in the proportions of visually impaired
children between the groups were assessed using logistic regression.
A 23-question assessment of CVI was also administered by the vision specialists.36 An average score was
derived from the answers to all available questions and analysed between the groups. This was based on
applicability of the questions as in some cases (such as blindness) the questions were not appropriate.
TRIAL DESIGN AND METHODS
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After analysis of the data, it was decided that the child who was blind should not have been given this
visual assessment and, therefore, was removed from the analysis. Originally, we had prespecified that we
would use a linear regression model to compare CVI scores. However, on inspection of the data, it became
clear that the data were negatively skewed (with 22% of children scoring the maximum score of 5; see
Results). Therefore, both a comparison of means and a non-parametric test were carried out to assess if
interpretation was similar.
Motor function and disability
Assessments of motor function and disability were made by a paediatric physiotherapist. Children were
assessed using the Movement ABC37 (see Appendix 5). Scores were then classified according to test
recommendations as mild (green), moderate (amber) or severe (red). These was analysed using ordinal
logistic regression. Children who could not complete the task owing to CP were automatically placed in
the severe category (as prespecified in the analysis plan).
Cerebral palsy
The number of diagnosed cases of CP was also compared between the two groups using logistic
regression. At 10 years, children were either diagnosed with CP or not diagnosed with CP. Severity of CP
was classified using the Gross Motor Function Classification System (GMFCS):39
l Level 1 – children walk at home, school, outdoors and in the community and can climb stairs without
the use of a railing.
l Level 2 – children walk in most settings and climb stairs holding onto a railing.
l Level 3 – children walk using a hand-held mobility device in most outdoor settings.
l Level 4 – children use methods of mobility that require physical assistance or powered mobility in
most settings.
l Level 5 – children are transported in a manual wheelchair in all settings.
Children without CP or with CP level 1 or 2 were classified as ambulant.
Emotional/behavioural function
Parents were asked to fill out the SDQ38 (see Appendix 6), which assesses how children behave in various
circumstances, with the final score being used to classify a child’s behaviour as ‘normal or ‘abnormal.
Differences in the overall score between the two groups were assessed using linear regression. Differences
between subscores were assessed using the Mann–Whitney U-test.
Sensitivity analysis
Several sensitivity analyses were conducted to test robustness of the results from the statistical analyses
and, in some cases, increase understanding of the relationship between the dependent and independent
variables. All were performed in the same way as the primary analysis. All sensitivity analyses were
prespecified before final analysis began. At 2 years, a binary outcome was used; therefore, the team decided
to duplicate this at 10 years (removing the sensorimotor element). Accounting for deaths in a trial that focuses
on neurodevelopmental outcomes is a hotly debated topic.40 The team felt that various methods should be
included as sensitivity analyses to ensure that results were consistent. Death was included in four different
ways. Initially, only the three deaths post 2-year follow-up were included and given a score of 0. The team
felt confident that this was appropriate given that these deaths could directly be linked to the child’s
disability. These three deaths were also included in a binary outcome that combined them with those who
had severe disability and an ordinal outcome of five categories where death was considered the worst
outcome. Last, all deaths were included in the binary outcome (including the eight deaths before 2 years).
Although this outcome reflects that used at 2 years it includes deaths which were unrelated to cognitive
ability. Cause of death before 2 years was difficult to determine and many were linked to neonatal
complications.
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Sensitivity analyses included:
l cognitive ability quotient (using BSID III/BAS III age-equivalent scores), including deaths as 0
l proportion alive and without severe cognitive disability at 10 years versus severely disabled/died owing
to disability
l grading of disability (mild/moderate/severe/dead) as an ordinal outcome
l imputation of missing data at 10 years (details below)
l cognitive ability quotient for the Bristol cohort only.
Similarly to Biering et al.,41 we chose to carry out five different imputation models, summarised in Table 1,
that made different assumptions about the data, particularly death.
Initially, baseline variables were assessed to determine if they were predictive of missingness in the primary
outcome using logistic regression. We then established, using linear regression, if they were appropriate
predictors of the primary model. Any baseline variables associated with the primary outcome of interest or
its missingness were added to the imputation model to inform the imputation process.
Using Stata 14’s ‘mi impute chained’ function, we created 40 imputations and used predictive mean matching,
as regression produced inappropriate imputations. A random seed of 65,898 was chosen for all models. All
children lost to follow-up were assumed to be alive, as imputing a death indicator variable proved impossible.
Subgroup analysis
Subgroups were used to test whether or not the effects of the DRIFT intervention were more pronounced
in certain subgroups of children. Although underpowered, tests of interaction between the dichotomised
variables and treatment therapy were carried out to test whether or not treatment effect differed between
subgroups. These interaction terms were added to the primary analysis model. All subgroup analyses were
prespecified in the analysis plan apart from maternal education.
Subgroup analyses included:
l gestation (≥ 28 weeks vs. < 28 weeks)
l grade of IVH (grade 3 vs. 4)
l age of randomisation (day 1–20 vs. ≥ 21 days)
l unilateral versus bilateral dilatation on ultrasonography at randomisation
l gender
l pre- and post-enhanced vigilance in 2006
l maternal education (post hoc).
TABLE 1 Multiple imputation assumptions
Assumption
Deaths
Lost to follow-upPre 2 years of age Post 2 years of age
1 ✗ CQ =missing, NI CQ =missing, NI
2 ✗ CQ =missing, death = 1 CQ =missing, death= 0
3 ✗ CQ = 0, NI CQ =missing, NI
4 ✗ CQ = 0, death= 1 CQ =missing, death= 0
5 ✗ ✗ CQ=missing, NI
CQ, cognitive quotient; death, indicator variable of death; NI, no indicator variable for death; ✗, removed from the
imputation model.
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Exploratory analyses
Although added before final analysis in April 2016, these were not prespecified in the trial protocol;
therefore, they are only exploratory analyses and should be interpreted with this in mind.
l Educational outcomes:
¢ mainstream schooling versus special school
¢ special educational needs (SEN) support, yes/no
¢ Key Stage 1 (KS1) scores
¢ Key Stage 2 (KS2) scores
¢ neurosurgical interventions after the neonatal period.
l Proportion with reservoirs.
l Shunt, yes/no (as assessed at 6 months).
l Death, yes/no (as assessed at 6 months and 2 years).
Neuroimaging
At 10 years, children assessed in Bristol who consented, and had no contraindications, to magnetic
resonance imaging (MRI) were eligible for structural brain MRI.
Structural MRI scans were acquired on a 3 tesla Siemens Skyra scanner (Erlangen, Germany) with the use
of a 32-channel radiofrequency head coil using 3D full volume T1-weighted inversion recovery gradient
echo. Magnetisation-Prepared Rapid Gradient-Echo sequence (MP-RAGE) was also acquired in the sagittal
plane, comprising 192 slices; repetition time: 1900 ms; time of echo: 2.2 ms; 0.9 mm isotropic voxel;
matrix: 128 × 128. T2 Turbo Spin Echo Axial plane time to acquisition: 2:53; voxel size: 0.4 × 0.4 × 3.0 mm;
40 slices.
Participants were scanned after parental consent, participant assent and a safety check. They were
excluded if contraindications to MRI were identified or if travel to Bristol was not possible.
Scans were assessed blinded to treatment allocation in one sitting by a team of three neonatal specialists
with neuroimaging interests (ASC, AW, KL) and two neurosurgeons (IP, KA). Each scan was classified by
consensus as follows:
l residual catheter tracts visible (frontal or occipital)
l parenchymal lesions
l ventricular reservoir in situ
l VP shunt in situ
l evidence of possible active hydrocephalus (dilated ventricles)
l residual clinical condition requiring neurosurgical referral.
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Chapter 3 Trial results
Participant flow
Figure 1 shows the layout of the trial and the different levels of drop-out and analysis. At 2 years’
follow-up there had been eight deaths but no loss to follow-up. At 10 years’ follow-up, four more deaths
had occurred as well as two children who could not be traced, one who declined to participate in the
follow-up and 10 non-responders.
Assessed for eligibility
(n = 82)
Excluded
(n = 5)
• Refused to participate,
   n = 4
• Infant found to be
   ineligible, n = 1
Randomised
(n = 77)
Allocation to DRIFT
(n = 39)
Allocation to standard
treatment
(n = 38)
Loss to follow-up (n = 0)
Deaths: aged < 2 years (n = 3)
Loss to follow-up (n = 0)
Deaths: aged < 2 years (n = 5)
2-year follow-up
10-year follow-up
Lost to follow-up (n = 2)
Survival status known (n = 34)
Lost to follow-up (n = 0)
Survival status known (n = 33)
Deaths: aged 2–10 years (n = 2)
Declined (n = 0)
No response (n = 4)
Deaths: aged 2–10 years (n = 2)
Declined (n = 1)
No response (n = 6)
Analysed at 2 years
(n = 36)
Analysed at 2 years
(n = 33)
Analysed at 10 years
(n = 28a)
Analysed at 10 years
(n = 24)
FIGURE 1 DRIFT CONSORT diagram. CONSORT, Consolidated Standards of Reporting Trials. a, One child did not
complete a cognitive text and, therefore, could not be included in the primary analysis.
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Recruitment
Originally, when the trial began, 77 babies were recruited to either receive DRIFT or standard treatment
(n = 39 and n = 38, respectively). During this period, the trial was temporarily stopped by the Data Monitoring
Committee, which was concerned by the rate of secondary haemorrhages; however, the trial was allowed to
continue with increased vigilance. After a further 6 months, an a priori interim analysis was performed and the
trial was closed owing to the low chance of seeing a significant result in the primary outcome – reduction in
shunt surgery/death.31 These children were then followed up and underwent numerous tests at approximately
age 2 years.32 Overall conclusions were that the 6-month time point was too soon after randomisation to be
able to evaluate the intervention, while the 2-year follow-up showed promising results in favour of the DRIFT
intervention. At 2 years’ follow-up there had been three deaths in the intervention arm and five in the standard
treatment arm. The intervention appeared to reduce severe cognitive/sensorimotor ability or death (adjusted
OR 0.25, 95% CI 0.08 to 0.82). At this time point, all of the parents consented to take part, giving a sample
size of 77 (including the eight deaths).
Approximately 8 years later (between September 2015 and April 2016), the parents were then contacted
and asked to take part in the 10-year follow-up study. Unfortunately, trial investigators were unable to find
a contact address or telephone number for two patients (in the DRIFT arm). This left 67 patients whose
survival status was known. Of these, two patients in the DRIFT arm and two patients in the standard
treatment arm died, one patient declined to participate (in the standard treatment arm) and 10 gave no
response, leaving 52 available for assessment (see Figure 1). The death certificates confirmed that two
deaths were due to the patient’s disability; in the other two cases, death certificates (one per arm) were
not available, so the cause of death was assumed to be disability based on these participants’ low scores at
2-year follow-up.
For the primary outcome, we obtained a cognitive score for 51 children: 27 in the DRIFT arm and 24 in the
control arm. The distribution of patients across centre and gender can be seen in Figure 2. In the sensitivity
analysis (substituting scores of 0 for those who died post 2 years), we had 29 and 26 for DRIFT and
standard treatment, respectively.
Baseline data
There were 77 patients who were randomised to the DRIFT trial; baseline comparisons are shown in Table 2.
The team prespecified in the analysis plan that any baseline characteristics that differed by > 10%/0.5 SDs
would be adjusted for in a sensitivity analysis. Only gender showed an imbalance of this magnitude at
0
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FIGURE 2 Assessment of children at 10 years, by centre.
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baseline; therefore, this sensitivity analysis was removed (given that this was already a prespecified covariate).
Birthweight showed moderate imbalance, approximately 0.36 SDs.
Among the 52 children available for follow-up assessments at 10 years, there were imbalances in gender
and birthweight (Table 3). There were 22 males in the DRIFT arm (79%), whereas the standard treatment
arm had a lower proportion of males (63%). Birthweight was much higher in the standard treatment arm
(mean 1322 g) than in the DRIFT arm (1102 g). After including the three deaths (used in the sensitivity
analysis of the primary analysis), this reduced the imbalance in gender to 9% and all other balances/
imbalances remained.
Among those assessed at 10 years, secondary haemorrhages were experienced by 29% of the DRIFT arm
compared with 13% of the standard treatment arm. On average, at 10 years, mothers in the DRIFT arm
had a higher education level than those in the standard treatment arm (Table 4). Unfortunately, this was
not recorded at baseline, so we cannot be sure where this sits within the causal pathway (i.e. whether this
is a confounding factor or determined as a result of the intervention).
TABLE 2 Baseline characteristics
Characteristic
DRIFT Standard treatment
N Mean (SD) or n (%) N Mean (SD) or n (%)
Total number of participants 39 38
Centre
Bristol, UK 39 27 (69) 38 27 (71)
Katowice, Poland 10 (26) 10 (26)
Glasgow, UK 1 (3) 1 (3)
Bergen, Norway 1 (3) 0 (0)
Sociodemographics at birth
Age at randomisation (days) 39 19.18 (4.73) 38 18.47 (4.95)
Gender: malea 39 29 (74) 38 24 (63)
Median IMD 2015b (IQR) 22 23.50 (29.00) 23 20.00 (24.00)
Clinical characteristics at birth
Birthweight (g) 39 1104.08 (346.23) 38 1251.21 (468.34)
Gestation (weeks) 39 27.69 (2.64) 38 28.21 (2.89)
Grade of IVH: 4 39 20 (51) 38 19 (50)
Maternal age at birth (years) 17 28.24 (6.70) 19 27.47 (6.06)
IMD, Index of Multiple Deprivation.
a Difference of 10%/0.5 SDs or higher between the groups.
b English IMD 2015 scores, UK Data Service Census Support, http://geoconvert.mimas.ac.uk/ (accessed 5 September 2016).
Higher scores indicate higher levels of deprivation. IMD based on the children’s home postcode at birth for those residing
in England only.
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In order to determine whether or not those lost to follow-up/died differed from those used in the final
analysis, baseline characteristics were compared (Table 5). Comparing baseline characteristics between
those in our sample with those who have died and those who have either declined or have been lost to
follow-up shows us the representativeness of our sample.
Overall, a greater proportion of infants from Poland were lost to follow-up than in the other centres,
largely because we are unable to trace patient records in Poland. This is because in Poland, in contrast to
the UK, there is no system of single personal numbers that allows patients to be traced. Overall, of those
who were lost to follow-up, 57% required a shunt while only 37% of those in our sample had a shunt.
There were fewer reservoirs among those lost to follow-up than our sample. Those who did not survive
were characteristically more vulnerable and, on average, had lower birthweights and shorter gestation
periods and were more likely to have a grade 4 IVH. However, surprisingly, the deprivation index was
lower for those who died, suggesting that they were less deprived than those who survived. Given the
small sample sizes for IMD, this is most likely a chance finding (p = 0.048).
TABLE 3 Baseline characteristics of those assessed at 10 years, by trial arm
Characteristic
Trial arm
DRIFT Standard treatment
N Mean (SD) or n (%) N Mean (SD) or n (%)
Total number of participants 28 24
Centre
Bristol, UK 28 23 (82) 24 19 (79)
Katowice, Poland 3 (11) 4 (17)
Glasgow, UK 1 (4) 1 (4)
Bergen, Norway 1 (4) 0 (0)
Sociodemographics at birth
Age at randomisation (days) 28 18.68 (5.00) 24 19.17 (4.53)
Gender: malea 28 22 (79) 24 15 (63)
Median IMD 2015b (IQR) 18 23.50 (30.00) 18 25.50 (14.00)
Clinical characteristics at birth
Birthweight (g)a 28 1101.89 (335.54) 24 1322.46 (534.68)
Gestation (weeks) 28 27.64 (2.56) 24 28.50 (3.05)
Grade of IVH: 4 28 14 (50) 24 11 (46)
Maternal age at birth (years) 14 28.50 (6.99) 12 28.17 (6.32)
IMD, Index of Multiple Deprivation.
a Difference of 10%/0.5 SDs or higher between the groups.
b English IMD 2015 scores, UK Data Service Census Support, http://geoconvert.mimas.ac.uk/ (accessed 5 September 2016).
Higher scores indicate higher levels of deprivation. IMD based on the children’s home postcode at birth for those residing
in England only.
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Numbers analysed
Contamination was not a problem in this trial as the intervention was given shortly after birth and could
not be requested by the control arm. When DRIFT was followed by persistent enlargement of ventricles
and excessive head growth (2 mm/day), management continued with LPs and ventricular reservoir.31
Among the original recruits (77 babies), there were three deaths in the DRIFT arm and five in the standard
treatment arm by 2 years. We are unable to determine the survival status of two children at 10 years.
Deaths and losses to follow-up were all relatively balanced between the group (chi-squared test: p ≥ 0.261)
(Table 6); therefore, the further analysis of infants lost to follow-up was not performed. The two children for
whom we could not establish survival status were explored in a sensitivity analysis by including them in a
best- and a worst-case scenario.
The numbers analysed for each outcome were also relatively balanced between the groups, especially for
the cognitive outcomes (chi-squared test, where the lowest p-value seen was 0.197) (Table 7).
TABLE 4 Characteristics at 2 and 10 years, by trial arm
Characteristic
Trial arm
DRIFT Standard treatment
N Mean (SD) or n (%) N Mean (SD) or n (%)
Measures at 2 years
Experienced second IVHa 28 8 (29) 24 3 (13)
Shunt 28 11 (39) 24 8 (33)
Reservoira 28 13 (46) 24 19 (79)
Infection 28 0 (0) 24 1 (4)
Measures at 10 years
Age at 10-year assessment (years) 28 10.56 (1.07) 24 10.76 (1.06)
Weight (kg) 28 35.41 (10.05) 23 34.73 (10.51)
Height (cm) 28 139.09 (12.22) 23 142.26 (11.34)
Head circumference (cm) 28 52.88 (2.53) 23 52.00 (3.43)
MRI performed at 10 years 28 15 (54) 24 12 (50)
Median IMD at 10 yearsb (IQR) 18 23.50 (30.00) 16 25.50 (24.00)
Maternal educationa
Left school at age 16 years 28 10 (36) 23 11 (48)
Further education 6 (21) 5 (22)
University degree 12 (43) 7 (30)
IMD, Index of Multiple Deprivation.
a Difference of 10%/0.5 SDs or higher between the groups.
b English IMD 2015 scores, UK Data Service Census Support, http://geoconvert.mimas.ac.uk/ (accessed 5 September 2016).
Higher scores indicate higher levels of deprivation. IMD based on the children’s home postcode at birth for those residing
in England only.
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TABLE 5 Baseline characteristics at 10 years: followed up, died or lost to follow-up
Characteristic
Sample at 10 years Deaths Uncontactable/declined
Na Mean (SD) or n (%) Na Mean (SD) or n (%) Na Mean (SD) or n (%)
Total number of participants 52 12 13
Centrea,b
Bristol, UK 52 42 (81) 12 6 (50) 13 6 (46)
Katowice, Poland 7 (13) 6 (40) 7 (54)
Glasgow, UK 2 (4) 0 (0) 0 (0)
Bergen, Norway 1 (2) 0 (0) 0 (0)
Sociodemographics at birth
Age at randomisation (days) 52 18.90 (4.75) 12 18.25 (5.75) 13 19.08 (4.57)
Gender: male 52 37 (71) 12 8 (67) 13 8 (62)
Median IMD 2015a,c (IQR) 36 25.00 (25.50) 5 9.00 (9.00) 4 21.5 (15.5)
Clinical characteristics at birth
Birthweight (g)a 52 1203.69 (448.17) 12 961.92 (151.53) 13 1266.92 (397.32)
Gestation (weeks)a 52 28.04 (2.80) 12 26.67 (2.35) 13 28.77 (2.71)
Experienced second IVH 52 11 (21) 12 2 (17) 13 3 (23)
Shuntb 52 19 (37) 12 5 (42) 13 7 (54)
Reservoirb 52 32 (62) 12 8 (67) 13 6 (46)
Infection 52 1 (2) 12 0 (0) 13 0 (0)
Grade of IVH: 4a 52 25 (48) 12 8 (67) 13 6 (46)
IMD, Index of Multiple Deprivation.
a Difference of 10%/0.5 SDs or higher between the 10-year sample and those children who died.
b Difference of 10%/0.5 SDs or higher between the 10-year sample and those lost to follow-up.
c English IMD 2015 scores, UK Data Service Census Support, http://geoconvert.mimas.ac.uk/ (accessed 5 September 2016).
Higher scores indicate higher levels of deprivation. IMD based on the children’s home postcode at birth for those residing
in England only.
TABLE 6 Losses to follow-up, by trial arm
Losses
Trial arm, n/N (%)
p-valueaDRIFT Standard treatment
Loss to follow-up
Deaths at 2 years of age 3/39 (8) 5/38 (13) 0.432
Complete loss to follow-upb 2/36 (6) 0/33 (0) –
Of those with known survival status
Deaths (post 2 years of age) as a result of disability 2/34 (6) 2/33 (6) 0.975
Deaths (post 2 years of age) not as a result of disability 0/34 (0) 0/33 (0) –
Declined participation 1/34 (3) 1/33 (3) 0.982
Non-responders 3/34 (9) 6/33 (18) 0.261
Attended 10-year follow-up 28/34 (82) 24/33 (73) 0.345
a Chi-squared test.
b These children were untraceable; therefore, we are unsure of their survival status.
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Outcomes
Primary outcomes
The primary hypothesis was that DRIFT would reduce severe cognitive disability in children assessed at
school age. The histogram in Figure 3 shows the distribution of cognitive quotient (CQ) scores (range
2.07–130.60 points). The graph shows a relatively normal distribution, albeit slightly bimodal. The box plot
in Figure 4 shows the distribution of CQ scores for each group, by trial arm. The results show that those in
the DRIFT arm had a median CQ score of 72.3 points, whereas those in the standard treatment arm had a
median CQ score of 46.7 points. The maximum CQ score was 130.6 points (achieved in the DRIFT arm),
which means that one child had a cognitive ability age 30% higher than his actual age. The highest score
achieved in the standard treatment arm was 107.2 points. There were two quotients of < 30 points in the
DRIFT arm, compared with seven in the standard treatment arm.
The histogram in Figure 5 shows the distribution of CQ scores (giving those who died a score of 0 points)
(range 0.00–130.60 points). The graph shows a relatively normal distribution, slightly skewed by the scores
of 0 points. The box plot in Figure 6 shows the scores by trial arm (giving those who died a score of 0 points).
The results show that those in the DRIFT arm had a median CQ score of 72.0 points whereas those in the
standard treatment arm had a median CQ score of 44.6 points.
TABLE 7 Denominators for assessment, by trial arm
Assessment
Trial arm, n (%)
p-valueaDRIFT Standard treatment
Completion
BAS III school age score 21 (78) 13 (54)
Full completion 21 (100) 12 (92) 0.197
Items missing (score created) 0 (0) 1 (8)
BAS III early year scores 4 (15) 5 (21)
Full completion 3 (75) 5 (100) 0.236
Items missing (score created) 1 (25) 0 (0)
BSID III scores 2 (7) 6 (25)
Full completion 2 (100) 3 (50) 0.206
Items missing 0 (0) 3 (50)
Visual assessment (parent) 27 (96) 24 (100) 0.350
Visual assessment (CVI) 28 (100) 21 (88) 0.054
Full completion 22 (79) 14 (67) 0.350
Items missing (score created) 6 (21) 7 (33)
Movement ABC 17 (61) 13 (54) 0.634
CP status 28 (100) 24 (100) –
SDQ 28 (100) 22 (92) 0.119
Full completion 26 (93) 22 (100) 0.201
Items missing (score created) 2 (7) 0 (0)
a Chi-squared test.
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FIGURE 3 Histogram of CQ scores, excluding deaths.
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FIGURE 4 Cognitive quotient scores, by trial arm. (a) Standard treatment; and (b) DRIFT.
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FIGURE 5 Sensitivity analysis: histogram of CQ scores, including deaths as a score of 0 points.
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Table 8 shows the results for the primary analysis, both including and excluding deaths. Given the larger
than expected attrition/death rate, precision was lower than hoped and was exacerbated further by large
SDs for the cognitive ability quotient. Despite this, results are in parallel with those at 2 years, with crude
estimates giving very weak evidence that the DRIFT intervention increases cognitive ability at 10 years
(p = 0.096). After adjusting for gender, birthweight and grade of IVH, this evidence was strengthened and
indicated that children who were in the DRIFT arm of the trial had, on average, a CQ score of 23.47 points
higher than those who received standard treatment (p = 0.009). This translates into a developmental
cognitive advantage of 2.5 years.
Given the look of the histogram (see Figure 3), we felt that it was important to explore the regression
assumptions to ensure that we had used the right model for our data. Looking at the mean and median of
our overall data, it was clear that they were similar: median 68.71 (IQR 54.28), mean 61.96 (SD 33.44).
The skewness and kurtosis were –0.21 and 2.08, respectively; therefore, we were satisfied that the
distribution was fairly symmetrical but slightly platykurtic (flat). The relationship between CQ score and
birthweight was fairly linear (linear regression p-value = 0.015; Figure 7). After running the adjusted model,
the residuals are approximately normally distributed (Figures 8 and 9). There is also no evidence to suggest
that there is an increasing variance over the values of the linear predictor (Figure 10). Therefore, the team
felt confident that a linear regression model was appropriate.
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FIGURE 6 Sensitivity analysis: CQ scores, by trial arm. (a) Standard treatment; and (b) DRIFT.
TABLE 8 Primary outcome: CQ score, by trial arma
Outcome
Trial arm, mean (SD)
Difference in
meansa (95% CI) p-valuea
Adjusted difference
in meansb (95% CI) p-valuebDRIFT
Standard
treatment
CQ score (points) 69.33 (30.06) 53.68 (35.70) 15.65 (–2.86 to 34.16) 0.096 23.47 (6.23 to 40.71) 0.009
CQ score (points)c 64.55 (34.04) 49.55 (37.22) 15.00 (–4.28 to 34.27) 0.125 22.33 (4.77 to 39.89) 0.014
a Linear regression, crude estimates.
b Linear regression, adjusted for gender, birthweight and grade of IVH (prespecified adjustment).
c Giving children who have died post 2 years of age a score of 0 points (sensitivity analysis).
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FIGURE 7 Regression diagnostic: relationship between CQ score and birthweight.
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FIGURE 8 Regression diagnostic: plotted histogram of residuals from the primary regression model.
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FIGURE 9 Regression diagnostics: residuals vs. normal distribution, estimated from the primary analysis model.
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Assessing prespecified covariants
Covariates were prespecified in the SAP and included birthweight, IVH grade and gender. These were the
same covariates used in the 2-year follow-up study in which these variables had previously been shown
to be imbalanced at 6-month follow-up. Table 9 shows how each of the covariates were individually
related to the cognitive ability quotient. The results show that, for each additional gram of birthweight,
CQ score at 10 years increased by 0.02 points (or 20 points per 1 kg). Those with grade 3 IVH had CQ scores
that were, on average, 24.37 points higher than those with grade 4 IVH. Girls had CQ scores that were, on
average, 13.96 points higher than those of boys. Figures 11 and 12 illustrate the spread of CQ scores across
gender and IVH grade.
Figure 13 shows the relationship between cognitive outcome and birthweight (g). Although the fitted line
appears to be curved, the outlying values of birthweight may be suggesting more curvature than there
actually is. A simple likelihood ratio test comparing the model with and without a quadratic term gives a
p-value of 0.346, suggesting that the null hypothesis of a linear relationship is not rejected.
It is also important to establish which of these three covariates are strengthening the relationship between
arm and CQ score. Table 10 shows the regression coefficients after adjustment for each covariate on its own.
All three covariates strengthen the relationship between cognitive score and trial arm. Birthweight has
proved to be the strongest adjustment, offering a strong difference between the groups with and without
deaths included as zero. Gender and IVH grade both strengthen the difference between the groups, but to
a smaller degree than birthweight.
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FIGURE 10 Regression diagnostics: residuals vs. predicted values, estimated from the primary analysis model.
TABLE 9 Cognitive quotient score, adjusting for each covariate independently, without trial arm
Covariate Difference in mean cognitive abilitya (95% CI) p-valuea
Cognitive ability at 10 years
Birthweight 0.02 (0.00 to 0.04) 0.035
IVHb –24.37 (–42.09 to –6.66) 0.008
Genderc –13.96 (–34.88 to 6.96) 0.186
a Linear regression.
b Coded 0 for grade 3 IVH and 1 for grade 4 IVH.
c Coded 0 for females and 1 for males.
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FIGURE 12 Relationship between cognitive outcome and grade of IVH. (a) Grade 3 IVH; and (b) grade 4 IVH.
500 1000 1500
0
50
100
C
Q
 s
co
re
 (
p
o
in
ts
)
150
30002000 2500
Birthweight (g)
Linear
Quadratic
Fitted values
FIGURE 13 Relationship between CQ score and birthweight with a linear and quadratic fit line.
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FIGURE 11 Relationship between cognitive outcome and gender. (a) Female; and (b) male.
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Although gender shows a very weak relationship with cognitive ability at 10 years, and only a small
adjustment when added as a covariate, it was imbalanced between the arms using the 10%/0.5 SDs rule.
IVH and birthweight are both predictors of cognitive score, so adjustment is appropriate. Overall, these
three covariates are appropriate for this analysis when taking into account both their relationship with the
outcome and distribution across arms.
Secondary outcomes
Visual
Figure 14 shows the four categories of sight by arm. The two lightest shades (solid outer line) make up a
positive visual outcome and the two darkest shades (dashed outer line) make up a negative visual outcome.
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FIGURE 14 Visual outcome, by trial arm. (a) Standard treatment; and (b) DRIFT.
TABLE 10 Cognitive quotient score by trial arm, adjusting for each covariate independently
CQ adjusted for Difference in meansa (95% CI) p-valuea Difference in meansb (95% CI) p-valueb
Birthweight 21.79 (3.90 to 39.67) 0.018 21.90 (3.68 to 40.12) 0.019
IVH grade 16.22 (–1.06 to 33.50) 0.065 16.56 (–1.29 to 34.41) 0.068
Gender 19.16 (0.63 to 37.70) 0.043 16.04 (–3.39 to 35.57) 0.104
a Linear regression.
b Linear regression, giving children who have died post 2 years of age a score of 0 (sensitivity analysis).
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There appears to be a larger proportion of ‘good’ visual outcomes in the DRIFT arm than in the standard
treatment arm. A logistic regression model below shows this difference in greater detail.
As well as this binary outcome, a 23-question visual assessment task (see Appendix 4) was also filled out
by vision specialists, who asked the parents various questions relating to CVI. Each question was scored
0–5, with higher scores indicating better cerebral vision.
Table 11 shows the results from the visual questions. For the binary visual outcome, this was answered for
27 and 24 children in the DRIFT arm and standard treatment arm, respectively. Overall, the results show
that those in the DRIFT arm were almost four times more likely to have a ‘good’ visual outcome than those
in the standard treatment arm (adjusted OR 3.73); however, the p-value provides only very weak evidence
to support this (p-value of 0.136). We realised after analysing the result that one child had been given the
CVI questionnaire even though he was blind. As a sensitivity analysis, we re-ran the analysis removing this
child as their result was considered inappropriate. The result remained unchanged. The mean score for CVI
is very slightly lower in the DRIFT arm; however, this result is consistent with chance (p-value of 0.502).
The Mann–Whitney U-test (a suitable non-parametric comparator to the regression model) gave a very
similar result, with even weaker evidence of a difference (p-value of 0.618). The team felt that it was
safe to conclude that there is little evidence that the intervention had an effect on parent-reported CVI.
Figures 15 and 16 show the distribution of CVI scores including and excluding the blind child, respectively.
Sensorimotor
It was prespecified that any child for whom the Movement ABC classification score was missing and who
was diagnosed with CP would automatically be placed in the severe category. The results of which are
presented in Figure 17.
Overall, the percentage of children with ‘severe’ sensorimotor scores was higher in the DRIFT group: 83%
vs. 74% (see Table 11). On closer inspection, it became clear that, although many more children were
slipping into this category, within this category, scores were higher in the DRIFT group [DRIFT, mean 38.69
(SD 11.76); standard treatment, mean 29.69 (SD 11.21) for the ‘severe’ category]. Figure 18 shows the
distribution of the sensorimotor scores, by group.
TABLE 11 Secondary outcome: parent-reported visual assessment results
Outcome
Trial arm, n (%)/mean (SD)
Differencea
(95% CI) p-valuea
Adjusted
differenceb
(95% CI) p-valuebDRIFT
Standard
treatment
Visual function (parent reported)
Good vision 23 (85%) 17 (71%) 2.37
(0.60 to 9.40)c
0.221c 3.73
(0.66 to 21.14)c
0.136c
CVI mean score 4.50 (0.70) 4.65 (0.38) –0.15
(–0.49 to 0.19)d
0.379d –0.12
(–0.47 to 0.24)d
0.502d
CVI median score 4.76 (0.67) 4.78 (0.48) 0.618e
CVI mean scoref 4.59 (0.55) 4.65 (0.38) –0.07
(–0.35 to 0.22)d
0.640d –0.04
(–0.33 to 0.26)d
0.793d
a Crude estimates.
b Adjusted for age, gender, birthweight and grade of IVH (prespecified adjustment).
c Logistic regression.
d Linear regression.
e Wilcoxon (Mann–Whitney) test.
f After removing any CVI scores for ‘blind’ children as these were considered inappropriate.
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FIGURE 16 Histogram of visual results after removal of blind child, by trial arm. (a) Standard treatment; and
(b) DRIFT.
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FIGURE 17 Sensorimotor ABC classification, by trial arm. (a) Standard treatment; and (b) DRIFT.
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FIGURE 15 Histogram of visual results, by trial arm. (a) Standard treatment; and (b) DRIFT.
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Closer inspection of the results showed that the assumption that children diagnosed with CP would score
< 55 was appropriate as the average sensorimotor score among children in this category who completed
the test was 28.92 (maximum 45.00) and the average sensorimotor score among children without a CP
diagnosis was 59.74 (maximum 88.00). Nevertheless, we conducted the same test, using only those who
had carried out the test, and achieved a score to see whether or not the assumption made an impact on
our findings. Reassuringly, this gave a very similar result.
It was also thought (post hoc) that a dichotomised outcome would also allow us to feel confident with the
conclusions drawn; therefore, this was carried out in the same way as the original (prespecified analysis)
but dichotomising on a score of < 55 or ≥ 55 (severe vs. moderate/mild disability). All of these analyses are
presented in Table 12.
Reassuringly, all of the models gave a similar result, with the conclusion that, although small positive effects
were seen in the DRIFT arm, after adjustment, these results were consistent with chance. Adjustment did
appear to change the conclusion from negative to positive for the DRIFT intervention. Looking at each of the
covariates individually, as with the primary outcome, birthweight caused the largest shift in treatment effect.
When using the continuous measure, we did achieve weak evidence to suggest that those in the DRIFT
intervention had better sensorimotor scores than the standard treatment arm; however, this was not
prespecified as an outcome and has a very low sample size. Therefore, there were no strong differences seen
between the arms when looking at motor ability.
The number of children diagnosed with CP was also prespecified as a secondary outcome. Children in the
DRIFT arm were 1.1 times more likely than those in the standard treatment arm to have CP (Table 13).
After adjustment for gender, birthweight and grade of IVH, this changed to a 63% lower odds of CP in
the DRIFT group; we know this is largely because those in the DRIFT group had less favourable baseline
characteristics. Looking at each of the covariates individually, as with the primary outcome, birthweight
caused the largest shift in treatment effect. Although the DRIFT arm included a higher percentage of
children with CP than the standard treatment arm (61% vs. 58%, respectively), it appeared that children in
the DRIFT arm were less likely to have CP categorised as severe. After adjustment, those in the DRIFT arm
were 80% more likely to be ambulant than those in the standard treatment arm. However, given the large
CI and p-value, there was not strong enough evidence to support this and it could have simply happened
by chance. As with the Movement ABC scoring, the results provided no substantial evidence to suggest a
difference between the groups.
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FIGURE 18 Sensorimotor score, by trial arm. (a) Standard treatment; and (b) DRIFT.
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Emotional/behavioural difficulties
To assess emotional and behavioural difficulties, parents were asked to fill in the SDQ (see Appendix 6).
The results are shown in Table 14. The subscales were almost all skewed to the left, indicating more
‘normal’ behaviour; therefore, subscales were assessed using the Mann–Whitney non-parametric U-test.
However, the total score did approximately follow a normal distribution and, therefore, was assessed using
linear regression (as prespecified in the analysis plan).
Higher values of the SDQ total score indicate more ‘abnormal’ behaviour and there was no difference
between the two groups (adjusted mean difference 2.01, 95% CI –2.78 to 6.81; p = 0.401). Although the
‘Conduct Problems’ subscale showed more favourable results in the standard treatment arm (p = 0.033),
this is, given the large number of tests carried out here for a single secondary outcome, most likely a
‘chance finding’. Figure 19 shows how the total score varied between groups.
Magnetic resonance imaging findings
There were no major differences relating to residual neurosurgical conditions needing referral; results are
presented by arm in Table 15.
Residual catheter tracks were more often seen in the standard treatment group and in association with
ventricular reservoirs.
TABLE 12 Secondary outcome: severity of sensorimotor disability
Outcome N (D : S)
DRIFT,
n (%)/
mean (SD)
Standard
treatment,
n (%)/mean
(SD)
Differencea
(95% CI) p-valuea
Adjusted
differenceb
(95% CI) p-valueb
Sensorimotor disabilityc,d
None/green (3) 2 (7%) 3 (14%)
Moderate/amber (2) 27 : 21 2 (7%) 2 (10%) 0.55
(0.13 to 2.34)e
0.416e 3.66
(0.33 to 40.34)e
0.290e
Severe/red (1) 23 (85%) 16 (76%)
Sensorimotor disabilityc,f
None/green (3) 2 (12%) 3 (23%)
Moderate/amber (2) 17 : 13 2 (12%) 2 (15%) 0.48
(0.10 to 2.29)e
0.359e 2.45
(0.23 to 26.66)e
0.461e
Severe/red (1) 13 (76%) 8 (62%)
Sensorimotor disabilityc,g
Severe/red vs. rest 27 : 21 23 (85%) 16 (76%) 1.80
(0.42 to 7.75)h
0.432 0.19
(0.012 to 3.29)h
0.257
Continuous scorei 17 : 13 45.94
(17.40)
46.96
(24.87)
–1.02
(–16.82 to 14.78)j
0.896 11.29
(–1.87 to 24.46)j
0.089
a Crude estimates.
b Adjusted for age, gender, birthweight and grade of IVH.
c Movement ABC-2 ‘Traffic Light’ System: green zone is described as ‘no movement difficulty detected’; amber zone as
‘suggests child is “at risk” of having a movement difficulty, monitoring required’ and red zone as ‘denotes a significant
movement difficulty’.
d A priori: ordinal logistic regression – if a child had a missing score for the Movement ABC classification and was
diagnosed with CP, they were automatically put into the severe category (prespecified outcome).
e Ordinal logistic regression.
f Post hoc check 1: ordinal logistic regression, using only those with a motor component score.
g Post hoc check 2: logistic regression, using a dichotomised outcome by combining moderate/mild motor disability.
h Logistic regression.
i Post hoc check 3: linear regression, using the continuous sensorimotor score.
j Linear regression.
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TABLE 14 Secondary outcome: SDQ results
Outcome N (D : S)
DRIFT,
mean (SD)a
Standard
treatment,
mean (SD)a
Difference
(95% CI)b p-valueb
Difference
(95% CI)c p-valuec
Emotional/behavioural difficulties (as predefined means)
Emotional symptomsd 28 : 22 3.32 (2.88) 2.59 (2.11) 0.502
Conduct problemse 28 : 22 2.68 (1.93) 1.55 (1.44) 0.033
Hyperactivity/
inattentionf
28 : 22 5.54 (3.18) 6.14 (2.85) 0.555
Peer relationships
g
28 : 22 3.36 (2.63) 3.09 (2.29) 0.760
Pro-social behaviourh 28 : 22 7.11 (2.63) 6.95 (2.28) 0.567
Impact scorei 28 : 22 2.46 (2.53) 2.23 (2.94) 0.530
SDQ total scorej 28 : 22 14.89 (8.48) 13.36 (6.59) 1.53
(–2.89 to 5.94)
0.490 2.01
(–2.78 to 6.81)
0.401
a The subscores had a skewed distribution; however, means (SDs) were used to make the direction clear as medians (IQR)
were often the same for both groups.
b Crude estimates, Mann–Whitney U-test for the skewed subscores and linear regression for the overall score.
c Adjusted for age, gender, birthweight and grade of IVH (for parametric tests only).
d On a scale of 0–10, where 0–3 corresponds to normal behaviour, 4 is borderline and 5–10 is abnormal.
e On a scale of 0–10, where 0–2 corresponds to normal behaviour, 3 is borderline and 4–10 is abnormal.
f On a scale of 0–10, where 0–5 corresponds to normal behaviour, 6 is borderline and 7–10 is abnormal.
g On a scale of 0–10, where 0–2 corresponds to normal behaviour, 3 is borderline and 4–10 is abnormal.
h On a scale of 0–10, where 6–10 corresponds to normal behaviour, 5 is borderline and 0–4 is abnormal.
i On a scale of 0–10, where 0 is normal, 1 is borderline and 2–10 is abnormal.
j A summation of the emotional symptoms, conduct problems, hyperactivity and peer relationships. On a scale of 0–40,
where 0–13 corresponds to normal behaviour, 14–16 is borderline and 17–40 is abnormal.
TABLE 13 Secondary outcome: CP diagnosis at 10 years
Outcome
DRIFT,
n (%)
Standard
treatment,
n (%)
Differencea
(95% CI) p-valuea
Differenceb
(95% CI) p-valueb
CP
Without CP 11 (39) 10 (42)
With CP 17 (61) 14 (58) 1.10 (0.36 to 3.35) 0.862 0.37 (0.07 to 2.00) 0.249
CP level
1 7 (41) 5 (36)
2 4 (24) 3 (21)
3 2 (12) 0 (0)
4 0 (0) 2 (14)
5 4 (24) 4 (29)
Ambulatory status
Ambulant (level 1–2)c 11 (65) 8 (57) 1.38 (0.32 to 5.88) 0.667 1.32 (0.24 to 7.25) 0.751
Non-ambulant (level 3–5)c 6 (35) 6 (43)
a Crude estimates.
b Adjusted for age, gender, birthweight and grade of IVH.
c For children with CP, they were categorised as ambulant (GMFCS level 1–2) or non-ambulant (GMFCS level 3–5).
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Sensitivity analyses
Various different techniques were used to address the primary analysis; these are of an exploratory nature.
Reassuringly, all of the analyses gave compatible results (presented in Table 16). As well as adjustments to
the way the outcome was measured, we also looked into adjustments for factors that may influence overall
effect. First, we adjusted for centre (post hoc) and established that this made no difference to the conclusion.
Compared with the original crude model, adjusting for centre weakened the average difference from 15.65 to
14.55 CQ points. The proportion of Polish children was higher in the standard treatment arm than in the DRIFT
arm and, consequently, the proportion of children from Bristol was higher in the DRIFT arm. On average, CQ
scores were higher in Bristol children than in Polish children (mean difference 14.40, 95% CI 14.08 to 42.88),
which may explain the weakened effect after adjustment for centre. The binary outcome gave very similar results
to the continuous CQ outcome. Both the unadjusted and adjusted models provided strong evidence to suggest
that DRIFT had a positive impact on children’s cognitive outcomes at 10 years. Using the figure estimated, we
calculated a number needed to treat (NNT) of three using the following calculation: 1/(14/26 – 8/29). Including
all deaths (pre and post 2 years of age) as a negative outcome gave the same result. The ordinal outcome,
unsurprisingly, offered a similar result to our primary analyses. In total, 50% of children in the standard
treatment arm had severe cognitive disability (> 3 SDs below the population mean), compared with 21% of
children in the DRIFT arm. Those in the DRIFT arm were at 3.63 times more likely to be in a higher category
(better outcome) than those in the standard treatment arm, after adjustment for covariates. This method
allowed us to differentiate between deaths and grades of disability by increasing the number of categories.
Adjustment for maternal education was a decision made after data analysis had begun. Unfortunately,
maternal age and education were not collected at baseline; however, maternal education (left school at
TABLE 15 Magnetic resonance imaging findings
Scan findings
Trial arm, n (%)
DRIFT (N= 16) Standard treatment (N= 12)
Residual catheter tract 3 (19) 4 (33)
Parenchymal lesion 7 (44) 5 (42)
Reservoir 9 (56) 9 (75)
VP shunt 7 (44) 4 (33)
Possible active hydrocephalus 2 (13) 1 (8)
Residual condition 2 (13) 2 (17)
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FIGURE 19 Strengths and Difficulties Questionnaire score, by trial arm. (a) Standard treatment; and (b) DRIFT.
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TABLE 16 Sensitivity analysis for the primary outcome
Sensitivity analysis N (D : S)
Trial arm, n (%)/mean (SD)
Difference (95% CI)a p-valuea
Adjusted difference
(95% CI)b p-valuebDRIFT Standard treatment
Original primary analysis
CQ 27 : 24 69.33 (30.06) 53.68 (35.70) 15.65 (–2.86 to 34.16)d 0.096 23.47 (6.23 to 40.71)d 0.009
CQc 29 : 26 64.55 (34.04) 49.55 (37.22) 15.00 (–4.28 to 34.27)d 0.125 22.33 (4.77 to 39.89)d 0.014
Continuous measure of cognitive ability
CQ (Bristol cohort only) 23 : 19 71.76 (27.42) 57.83 (34.78) 13.93 (–5.46 to 33.33)d 0.154 24.88 (6.82 to 42.94)d 0.008
CQ (Bristol cohort only)c 24 : 20 68.77 (30.56) 54.94 (36.24) 13.84 (–6.48 to 34.15)d 0.177 23.27 (4.65 to 41.88)d 0.016
Binary measuree
Alive and without severe cognitive
disability (post 2 years)
29 : 26 21 (72%) 11 (42%) 3.58 (1.16 to 11.04)f 0.026 9.96 (2.12 to 46.67)f 0.004
Alive and without severe cognitive
disability (including all 12 deaths)
32 : 31 21 (66%) 11 (35%) 3.47 (1.23 to 9.78)f 0.019 7.69 (1.96 to 30.11)f 0.003
Cognitive disability category
1. Dead 29 : 26 2 (7%) 2 (8%)
2. Severe 6 (21%) 13 (50%)
3. Moderate 7 (24%) 2 (8%) 2.04 (0.77 to 5.42)g 0.151 3.63 (1.21 to 10.90)g 0.022
4. Mild 8 (28%) 4 (15%)
5. No cognitive disability 6 (21%) 5 (19%)
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Sensitivity analysis N (D : S)
Trial arm, n (%)/mean (SD)
Difference (95% CI)a p-valuea
Adjusted difference
(95% CI)b p-valuebDRIFT Standard treatment
Additional adjustments for the original primary analysis (CQ score)
Adjusted for centre 27 : 24 69.33 (30.06) 53.68 (35.70) 13.76 (–4.45 to 31.92)d 0.135 22.00 (5.69 to 38.30)d,h 0.009
Adjusted for centre (Bristol vs. others) 27 : 24 69.33 (30.06) 53.68 (35.70) 14.55 (–3.78 to 32.87)d 0.117 23.19 (6.35 to 40.04)d,h 0.008
Adjusted for maternal educationi 27 : 23 69.33 (30.06) 55.90 (34.77) 11.50 (–6.86 to 29.87)d 0.214 20.08 (2.96 to 37.21)d,h 0.023
Adjusted for baseline imbalancej 27 : 24 69.33 (30.06) 53.68 (35.70) 24.58 (6.69 to 42.46)d 0.008
D, DRIFT; S, standard treatment.
a Crude estimates.
b Adjusted for gender, birthweight and grade of IVH, unless otherwise stated.
c Giving children who have died post 2 years a score of 0.
d Linear regression.
e Alive and well vs. severely disabled/died owing to disability.
f Logistic regression.
g Ordinal logistic regression.
h Additional adjustment for gender, birthweight and IVH.
i Using maternal education measured at 10 years (missing for one standard treatment patient), making the assumption that maternal education collected at 10 years has not changed
since baseline.
j Factors imbalanced at baseline between those analysed at 10 years were gender and birthweight (additional adjustment for IVH was not carried out as it would duplicate the primary analysis).
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16 years of age, further education or university degree) was measured at 10 years. The team felt that,
although imprecise, this was an adequate estimate of maternal education at baseline. The mean CQ score
for infants born to ‘university degree’ mothers was 75.49 points, for infants born to ‘further education’
mothers was 50.84 points and for infants bon to mothers who ‘left school at 16’ was 57.84 points
(p = 0.094). The proportion of mothers with a university degree was higher in the DRIFT arm than in the
control arm (43% vs. 30%). Therefore, adjustment resulted in a weakened effect estimate. However, it
should be pointed out that adjustment for birthweight, IVH, gender and maternal education still produced
compatible results to the primary analysis (p = 0.023).
An adjustment for imbalances at baseline was prespecified in the analysis plan and defined as any
difference of ≥ 10%/0.5 SDs between the groups. Referring back to Table 2, the variables classed as
imbalanced were gender and birthweight. Adjustment for only these two factors resulted in strong
evidence that the DRIFT intervention improves cognitive outcome at 10 years.
Best- and worst-case scenarios
Unfortunately, two patients could not be followed up at 10 years and their survival status was, therefore,
unknown. Given the number of deaths post 2 years of age, it is unlikely that these patients would have
died; however, it is important to understand the significance of these patients by calculating the extremes.
Therefore, for a best-case scenario, the two children in the DRIFT arm were presumed to be alive and well
(with the median score of their group), and vice versa for the worst-case scenario; the two children in the
DRIFT arm were presumed, dead (with a score of 0). Results from these analyses are presented in Table 17.
These assumptions are very extreme and the results, as expected, show that the best-case scenario
strengthens the unadjusted treatment effect, whereas the worst-case scenario weakens it to produce a
treatment difference consistent with chance (but still in favour of DRIFT).
Multiple imputation
In order to carry out a multiple imputation model, we must first assess whether or not the data are missing
at random (MAR). In Figures 20 and 21, the red markers highlight the gestations/birthweights when the
CQ score is missing. When checking cognitive scores across gestation and birthweight levels, it appears
that missing data are evenly spread across these variables. At first glance, the MAR assumption appears to
be valid across these two variables.
TABLE 17 Best- and worst-case scenarios
Sensitivity analysis N (D : S)
Trial arm, mean (SD)
Difference
(95% CI)a p-valuea
Adjusted
difference
(95% CI)b p-valuebDRIFT
Standard
treatment
Different scenarios for the two patients with unknown survival status
Best-case scenarioc 31 : 26 65.04
(32.94)
49.55
(37.22)
15.49
(–3.13 to 34.12)
0.101 20.67
(3.68 to 37.65)
0.018
Worst-case scenariod 31 : 26 60.38
(36.62)
49.55
(37.22)
10.83
(–8.83 to 30.50)
0.274 15.28
(–3.72 to 34.29)
0.113
D, DRIFT; S, standard treatment.
a Crude estimates.
b Adjusted for gender, birthweight and grade of IVH.
c Assuming the two children in the DRIFT arm were all alive and well (with the median score for their group) at 10 years.
d Assuming the two children in the DRIFT arm died.
Giving children who have died post 2 years of age a score of 0.
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Logistic regression was used to test which baseline characteristics and follow-up data points were predictive
of missing CQ at 10 years. There were several variables that were predictive of missing CQ [centre, receiving
a shunt at 2 years, mental development quotient (DQ) at 2 years and disability level at 2 years]. There were
also several variables that were useful predictors of CQ [trial arm, age at entry (days), birthweight, gestation,
IVH grade, the following measures at 2 years: mental DQ, motor DQ, gait, sitting, hand, speech, vision,
disability, and the following measures at 10 years: vision, seizures, shunts, cerebral palsy, sensorimotor,
hyperactivity, peer relationships and prosocial].
To examine the relationship between mental and motor DQs at 2 years and CQ at 10 years, we created a
scatterplot. The scatterplots in Figures 22 and 23 show how well a straight line fits each of these relationships.
Assumptions for each multiple imputation model are described in Table 1. Each assumption has its own
strengths and weaknesses, each treating death due to disability in a different way. The results are
presented in Table 18.
To ignore death completely would result in a stronger result (p = 0.005 vs. p = 0.009). To impute for those
deaths would offer a slightly stronger result (p ≤ 0.008 vs. p = 0.009), whereas to give them a hypothesised
value of zero slightly weakens the result (p ≥ 0.015 vs. p = 0.009). However, in the five models developed
here, the results remain compatible with the main analysis and with each other.
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FIGURE 21 Testing the MAR assumption: birthweight.
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TABLE 18 Multiple imputation
Sensitivity
analysis N (D : S)
Trial arm, mean (SE)
Difference
(95% CI)a p-valuea
Adjusted
difference
(95% CI)b p-valuebDRIFT
Standard
treatment
Imputation of cognitive DQ
Assumption 1 36 : 33 65.24 (5.63) 50.81 (6.23) 14.43
(–2.10 to 30.96)
0.086 21.17
(5.66 to 36.68)
0.008
Assumption 2 36 : 33 65.42 (5.45) 50.87 (6.31) 14.54
(–1.98 to 31.07)
0.083 21.42
(6.21 to 36.64)
0.007
Assumption 3 36 : 33 62.95 (5.80) 49.41 (6.44) 13.55
(–3.84 to 30.93)
0.124 20.53
(4.49 to 36.56)
0.013
Assumption 4 36 : 33 62.80 (5.91) 49.58 (6.47) 13.22
(–4.49 to 30.93)
0.140 20.08
(3.79 to 36.38)
0.017
Assumption 5 34 : 31 66.85 (5.42) 53.70 (6.43) 13.14
(–3.67 to 29.96)
0.123 20.47
(4.62 to 36.31)
0.012
D, DRIFT; S, standard treatment.
a Crude estimates using a linear regression model.
b Linear regression model, adjusted for gender, birthweight and grade of IVH.
Using ‘mi impute chained’ with the following predictors: at randomisation – arm, gender, age at entry (days), centre,
birthweight and gestation; at 2 years – shunt, seizure, speech, vision, hearing, disability, sitting, hand, mental DQ and
motor DQ; at 10 years – vision, hearing, seizures, shunts, oxygen and CP (and indicator of death, where appropriate).
0 50
0
50
100
C
Q
 s
co
re
 (
at
 1
0 
ye
ar
s)
 (
p
o
in
ts
)
150
100
Mental DQ (at 2 years)
Individuals
Fitted values
FIGURE 22 Relationship between 2-year and 10-year scores: mental DQ.
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Subgroup analysis
Subgroup analyses were almost all selected a priori and explored using formal tests of interaction; maternal
education was the only post hoc subgroup analysis. Given the small sample size in this study, these
analyses were heavily underpowered, resulting in the risk of false-negative results. With this in mind, focus
was concentrated more on the estimates and CIs than on the p-values. Subgroup analyses results are
presented in Table 19.
The interaction effect mean differences can be interpreted as the effect of DRIFT compared with standard
treatment in one subgroup relative to the effect in the other subgroup. Overall, no obvious differences were
seen in the subgroups. Of all of these analyses, the only one that may warrant further consideration is
gestation. After adjustment for birthweight and gender, the difference between the arms appeared to be
greater for those with gestation ≥ 28 weeks (18.85 points) than for those with gestation < 28 days. This
offers very weak evidence to suggest that DRIFT may be more effective for those with higher gestation;
however, the unadjusted results were in the opposite direction. The unadjusted results for grade of IVH
suggested that the DRIFT may be more effective in those with grade 4 IVH; however, adjustment weakened
this result. Scores appeared to be much higher for those who were cared for with increased vigilance after the
stopping period; however, the interaction is difficult to interpret because of the small samples provided in the
cross-tabulation. As stated previously, the small sample sizes in each subgroup mean that these analyses are
heavily underpowered and should be interpreted with caution.
Exploratory analysis
The team collected some additional information on the children’s educational level at KS1 and KS2
(provided children had reached this level) from each of the children’s named teacher. The expected level
for children at KS1and KS2 is 2b and 4b, respectively. Those who were scored using the P levelling were
below the level of the tests. Whether or not the child received SEN support was also recorded on the
Client Service Receipt Inventory (CSRI),42 along with data on speech and language therapy (SLT) attendance
in the past 6 months and special school attendance in the past 12 months. All results are in Table 20.
As the sample sizes for educational levels are small (27 children with KS1 scores and 17 children with KS2
scores), more emphasis should be put on descriptives than on p-values. Table 20 shows that children
in the DRIFT arm were more likely than those in the standard treatment arm to score level 1 or above (71%
vs. 46% at KS1; 63% vs. 44% at KS2). However, the number of children scoring above average was similar
in each group (21% vs. 23% for KS1; 25% vs. 22% for KS2). Using the SEN data, it appears that the
percentage of children receiving SEN support is similar in each arm, but slightly higher in the DRIFT arm.
More data were available for SLT and special school attendance. After adjustment, those in the DRIFT arm had
lower odds (0.27) of special school attendance in the last 12 months than those in the standard treatment arm
(p= 0.059). They also had lower odds (0.30) of attending SLT sessions in the previous 6 months (p = 0.079).
These outcomes were not prespecified in the trial protocol and sample sizes here were very small; therefore,
there should be no overinterpretation of the results.
Binary visual outcomes
This is an exploratory analysis with low numbers and multiple testing. Thus, any significance attached to findings
(or lack of them) is not so important but, rather, the pattern of observations help to generate hypotheses for
future study. Table 21 gives the baseline characteristics of those who were followed up at 10 years.
Table 22 shows the visual results, as assessed by the blinded ophthalmologist. All negative outcomes are
coded as ‘1’ and positive outcomes as ‘0’. When comparing DRIFT with standard treatment, almost all
differences are consistent with chance. Initially, before adjustment, the DRIFT arm had more horizontal
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TABLE 19 Subgroup analysis for cognitive disability scores
Subgroup N (D : S)
Subgroup specific, mean (SD)
Interactiona (95% CI) p-valuea Interactionb (95% CI) p-valuebDRIFT Standard treatment
Gestation (weeks)
< 28 15 : 10 62.51 (28.42) 42.86 (30.68) 3.20 (–33.72 to 40.11) 0.862 –18.85 (–54.67 to 16.98) 0.295
≥ 28 12 : 14 77.85 (31.06) 61.40 (38.07)
Grade of IVH
3 14 : 13 75.60 (26.07) 71.10 (36.34) 24.99 (–9.24 to 59.23) 0.149 15.65 (–19.80 to 51.11) 0.379
4 13 : 11 62.58 (33.56) 33.09 (22.05)
Age (days)c
< 21 15 : 15 75.22 (30.11) 60.71 (37.34) –5.48 (–42.92 to 31.96) 0.770 –5.02 (–38.26 to 28.23) 0.762
≥ 21 12 : 9 61.96 (29.58) 41.96 (31.27)
Dilationd
Unilateral 4 : 4 64.00 (23.67) 35.37 (16.91) 15.72 (–35.36 to 66.81) 0.539 6.80 (–39.98 to 53.58) 0.771
Bilateral 23 : 20 70.25 (31.39) 57.34 (37.59)
Gender
Male 22 : 15 65.33 (31.60) 47.57 (34.38) –5.27 (–47.71 to 37.17) 0.804 –3.60 (–42.06 to 34.85) 0.851
Female 5 : 9 86.90 (12.50) 63.86 (37.55)
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Subgroup N (D : S)
Subgroup specific, mean (SD)
Interactiona (95% CI) p-valuea Interactionb (95% CI) p-valuebDRIFT Standard treatment
Vigilancee
Pre-enhanced 22 : 23 67.65 (33.09) 51.49 (34.82) –43.45 (–117.82 to 30.92) 0.246 –15.24 (–84.51 to 54.03) 0.660
Post-enhanced 5 : 1 76.69 (6.40) 103.98 (0.00)
Maternal educationf
Lowf 10 : 11 64.16 (37.76) 52.10 (31.79) –0.93 (–38.99 to 37.12) 0.961 –15.84 (–50.78 to 19.10) 0.366
High 17 : 12 72.37 (25.29) 59.38 (38.37)
D, DRIFT; S, standard treatment.
a Crude estimates from the interaction term in the linear regression model.
b Estimates from the interaction term in the logistic regression model, adjusted for gender, birthweight and IVH, as appropriate.
c Age at randomisation.
d Dilation on ultrasonogarphy at randomisation.
e In 2006, the trial was temporarily stopped as the committee members were concerned about the large number of secondary haemorrhages in the DRIFT arm. After this time, seven more
patients were recruited during an ‘enhanced vigilance’ period.
f Maternal education was collected at 10 years and, therefore, only classes as an indicator of education at baseline (to be viewed with caution). This was classed as ‘low’ if the mother left
school at age 16 years and ‘high’ if the mother carried on with further education post age 16 years and/or went to university.
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TABLE 20 Educational outcomes, by trial arm
Outcome
Trial arm, n (%)
ORa (95% CI) p-valuea ORb (95% CI) p-valuebDRIFT
Standard
treatment
KS1 scoresc
Level 1 or above 10 (71) 6 (46) 2.92
(0.59 to 14.33)
0.187 7.37
(0.82 to 66.10)
0.074
Level P1–P8 4 (29) 7 (54)
Unknown 25 (64) 25 (76)
Level ≥ 2bd 3 (21) 3 (23) 0.91
(0.15 to 5.58)
0.918 1.24
(0.16 to 9.74)
0.840
KS2 scoresc
Level 1 or above 5 (63) 4 (44) 2.08
(0.30 to 14.55)
0.459 e e
Level P1–P8 3 (38) 5 (56)
Unknown 20 (51) 21 (55)
Too young to assess 11 (28) 8 (21)
Level ≥ 4bf 2 (25) 2 (22) 1.17
(0.12 to 10.99)
0.893 1.52
(0.13 to 18.31)
0.743
SEN support
Yes 11 (65) 10 (56) 1.47
(0.38 to 5.72)
0.581 0.88
(0.14 to 5.39)
0.888
No 6 (35) 8 (44)
Special school attendance in the past 12 months
Yes 8 (29) 11 (48) 0.44
(0.14 to 1.39)
0.161 0.27
(0.07 to 1.05)
0.059
No 20 (71) 12 (52)
SLT in last 6 months?
Yes 9 (35) 11 (61) 0.34
(0.10 to 1.17)
0.087 0.30
(0.08 to 1.15)
0.079
No 17 (65) 7 (39)
a Crude adjustments using logistic regression.
b Logistic regression model, adjusted for grade of IVH, gender and birthweight.
c The children analysed at KS1 do not necessarily match the children analysed at KS2.
d Level 2b is the average level of achievement at KS1.
e There were too few observations to carry out a test.
f Level 4b is the average level of achievement at KS2.
TABLE 21 Baseline characteristics for those having visual assessments at 10 years
Characteristic N (D : S)
Trial arm, n (%)
N (3 : 4)
IVH grade, n (%)
DRIFT Standard treatment 3 4
Gender 28 : 24 22 (79%) 15 (63%) 27 : 25 19 (70%) 18 (72%)
Mean birthweight (g) 28 : 24 1102 (336) 1322 (535) 27 : 25 1333 (537) 1064 (274)
IVH grade 4 28 : 24 14 (50%) 11 (46%) – – –
D, DRIFT; S, standard treatment.
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pursuit scores that were < 5. However, after adjustment for IVH, gender and birthweight, this difference
was reduced. This is unsurprising given that those in the DRIFT arm were suffering from less favourable
baseline characteristics. The percentage of children who could not do rectangles was smaller in the DRIFT
arm than in the standard treatment arm, a difference that was after adjustment for baseline factors. It may
be that this, given the large number of tests, is a chance finding. These should be considered as exploratory
and ‘hypothesis generating’.
TABLE 22 Binary visual outcomes
Outcome N (D : S)
Trial arm, n (%)
OR (95% CI)a p-valueaDRIFT
Standard
treatment
Possible/definite field loss 17 : 13 2 (12) 3 (23) 0.44 (0.06 to 3.16) 0.417b
Nystagmus 19 : 16 4 (21) 2 (13) 1.87 (0.29 to 11.84) 0.508b
Could not do rectangles (open or closed)
vs. could
18 : 14 3 (17) 5 (36) 0.36 (0.07 to 1.88) 0.226b
Could not do postbox vs. could 19 : 14 1 (5) 1 (7) 0.72 (0.04 to 12.64) 0.824b
Poor binocular, left or right vision (all > 0) 20 : 16 5 (25) 7 (44) 0.43 (0.10 to 1.76) 0.240b
Strabismus 19 : 16 12 (63) 10 (63) 1.03 (0.26 to 4.07) 0.968b
Horizontal pursuit < 5 19 : 14 14 (74) 5 (36) 5.04 (1.13 to 22.50) 0.034b
Vertical pursuit < 5 19 : 13 12 (63) 5 (38) 2.74 (0.64 to 11.75) 0.174b
Horizontal saccade < 5 19 : 14 14 (74) 5 (36) 5.04 (1.13 to 22.50) 0.034b
Vertical saccade < 5 19 : 13 11 (58) 5 (38) 2.20 (0.52 to 9.30) 0.284b
Contour score of > 1 16 : 12 4 (25) 4 (33) 0.67 (0.13 to 3.47) 0.630b
N (3 : 4)
IVH grade, n (%)
OR (95% CI)a p-valuea3 4
Possible/definite field loss 16 : 14 0 (0) 5 (36) – 0.014c
Nystagmus 19 : 16 1 (5) 5 (31) 8.18 (0.84 to 79.54) 0.070b
Could not do rectangles (open or closed)
vs. could
18 : 14 3 (17) 5 (36) 2.78 (0.53 to 14.50) 0.226b
Could not do postbox vs. could 18 : 15 0 (0) 2 (13) – 0.199c
Poor binocular, left or right vision (all > 0) 21 : 15 2 (10) 10 (67) 19.00 (3.11 to 116.1) 0.001b
Strabismus 20 : 15 9 (45) 13 (87) 7.94 (1.41 to 44.80) 0.019b
Horizontal pursuit < 5 18 : 15 7 (39) 12 (80) 6.29 (1.29 to 30.54) 0.023b
Vertical pursuit < 5 17 : 15 5 (29) 12 (80) 9.60 (1.86 to 49.48) 0.007b
Horizontal saccade < 5 18 : 15 7 (39) 12 (80) 6.29 (1.29 to 30.54) 0.023b
Vertical saccade < 5 17 : 15 4 (24) 12 (80) 13.00 (2.40 to 70.46) 0.003b
Contour score of > 1 17 : 11 2 (12) 6 (55) 9.00 (1.35 to 59.78) 0.023b
D, DRIFT; S, standard treatment.
a Crude adjustments.
b Logistic regression.
c Fisher’s exact test was used when the independent variable was a perfect predictor.
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When comparing grade 3 IVH with grade 4, visual outcomes at 10 years were very different. For almost all binary
outcomes, there was evidence to suggest that the odds of negative outcomes were higher for those in grade 4
than for those in grade 3. We observed no difference in the number of children who could not do rectangles.
All other visual outcomes were substantially worse for the grade 4 children than for the grade 3 children.
Owing to perfect prediction with the covariates, most of the models could not be adjusted. ‘Poor binocular,
right or left vision’ was defined as ‘1’ for those who scored > 0 (and answered at least one) for all of the
following: binocular – distance acuity single optotype; binocular – distance acuity; right – distance acuity
single optotype; right – distance acuity croweded optotype; left – distance acuity single optotype; and
left – distance acuity crowded optotype. If participants scored ≥ 0 for any of those questions, the score
was defined as ‘0’. For ‘poor binocular, right or left vision’, gender and IVH were both perfect predictors.
In total, 0% of girls with grade 3 IVH and 33% of girls with grade 4 IVH had ‘poor binocular, right or left
vision’, compared with 13% of boys with grade 3 IVH and 75% of boys with grade 4 IVH.
Possible or definite field loss was defined as ‘1’ if the binocular visual field was variably or definitely
reduced and as ‘0’ if normal. Of those with grade 4 IVH, 36% had field loss, compared with 0% of those
with grade 3 IVH; therefore, this adjustment was not made for the arm comparison and the chi-squared
test was used for the comparison between IVH grades. Nystagmus classed as ‘None’, ‘in PP’ or ‘at
extremes of gaze’. Only those with nystagmus ‘in PP’ were defined as ‘1’ for nystagmus. Gender was a
perfect predictor for this as 22% of boys had nystagmus, compared with 0% of girls; therefore, the
adjusted model could not be performed. ‘Could not do rectangles (open or closed)’ was defined as ‘1’ if
the child ‘could not do’ either the open or closed rectangle and defined as ‘0’ if they were ‘normal’ or only
had ‘some problems’ for both. ‘Could not do postbox’ was defined in the same way. IVH was a perfect
predictor for this, as 13% of those with grade 4 IVH could not do the postbox, compared with 0% of
those with grade 3 IVH. Strabismus was defined as ‘1’ for those who did not achieve ‘normal’ for the
cover test unaided at 33 cm and as ‘0’ for those who achieved ‘normal’.
Neonatal outcomes at 2 years
Information collected from both groups at 2 years was compared and is presented in Table 23. As reported
previously, there were eight deaths before the 2-year time point: five in the standard treatment arm and
three in the DRIFT arm. There were 16 (41%) VP shunts in the DRIFT arm and 15 (39%) in the standard
treatment arm.32 Reservoirs were required by 28 (74%) children in the standard treatment arm and by
18 (46%) in the DRIFT arm (adjusted OR 0.27, 95% CI 0.10 to 0.76).
Harms
Despite the excess secondary haemorrhages in the DRIFT group, the primary outcomes were better and the
secondary outcomes no worse than in the standard treatment group. It does not appear that secondary
haemorrhages that occurred during the DRIFT procedure had a long-term detrimental effect.
Visual field defects were also no more frequent in the DRIFT group despite insertion of the occipital
irrigation catheters.
High-resolution structural brain MRI at 10 years showed no evidence of damage associated with insertion
of the DRIFT irrigation catheters. A larger proportion of the standard treatment group required ventricular
reservoirs, and more residual frontal tracts associated with reservoirs were seen in the standard treatment
group. There was no difference in ongoing neurosurgical problems between the treatment arms at age
10 years.
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TABLE 23 Outcomes at 2 years
Outcome
Trial arm, n (%)
Differencea (95% CI) p-valuea Differenceb (95% CI) p-valuebDRIFT
Standard
treatment
Death
Yes 3 (8) 5 (13) 0.55 (0.12 to 2.48) 0.437 0.45 (0.10 to 2.14) 0.317
No 36 (92) 33 (87)
Shuntc
Yes 16 (41) 15 (39) 1.07 (0.43 to 2.65) 0.890 0.99 (0.38 to 2.61) 0.982
No 23 (59) 23 (61)
Reservoir
Yes 18 (46) 28 (74) 0.31 (0.12 to 0.80) 0.015 0.27 (0.10 to 0.76) 0.013
No 21 (54) 10 (26)
a Crude estimates using logistic regression.
b Logistic regression model, adjusted for birthweight, gender and grade of IVH.
c One patient in the DRIFT arm required a shunt after 2 years. Adding this child did not affect the result.
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Chapter 4 Economic analysis of the costs and
outcomes of the DRIFT intervention
Introduction
The National Institute for Health and Care Excellence (NICE) currently recommends that DRIFT should not
be used routinely in the NHS, but only in the context of research.43 If DRIFT were to be used in routine
NHS care, it is important to consider whether or not the upfront costs of the procedure are justified by
improvements in patient outcomes and/or reduced costs of care later in life. The original RCT and early
follow-up at 2 years of age did not collect detailed resource use data or include an economic evaluation.
Therefore, we cannot conduct a comprehensive economic evaluation comparing the cumulative costs
of care, survival and QoL following DRIFT and standard care. In our primary economic evaluation, we
conducted a cost–consequence analysis44 assessing whether DRIFT increases or reduces NHS secondary
care resource use since birth, and providing a more detailed snapshot of health care, social care and
educational costs, productivity losses and QoL among survivors at follow-up after 10 years. If DRIFT
improves outcomes or reduces costs of care at school age, it is likely to become more cost-effective over
the future lifetime of survivors. In exploratory analyses, we use a decision analytical model to extrapolate
costs and outcomes to age 18 years.
A total of 54 of the 77 children in the DRIFT study were recruited in Bristol and are the focus of the
economic evaluation (Figure 24). We excluded children recruited at other centres in other countries owing
to the expense and logistical difficulty of tracking down hospital notes and linking to routine hospital data
in the years since birth.
Randomised
(n = 77)
Allocated to DRIFT
(n = 39)
Received allocated intervention
(n = 39)
Allocated to standard care
(n = 38)
Received allocated intervention
(n = 38)
Eligible for economic analyses
(n = 27)
Excluded
Poland, n = 10
Norway, n = 1
Scotland, n = 1
Eligible for economic analysis
(n = 27)
Excluded
Poland, n = 10
Scotland, n = 1
Cases included in analysis
Notes/HES on Bristol neonatal stay
(n = 24)
Notes/HES on transfer neonatal stay
(n = 27)
HES on postnatal episodes
(n = 18)
10-year follow-up QoL
(n = 23)
Cases included in analysis
Notes/HES on Bristol neonatal stay
(n = 23)
Notes/HES on transfer neonatal stay
(n = 26)
HES on postnatal episodes
(n = 16)
10-year follow-up QoL
(n = 18)
FIGURE 24 The CONSORT diagram for the cost–consequence analysis. CONSORT, Consolidated Standards of
Reporting Trials; HES, Hospital Episode Statistics.
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Methods
Resource use, data collection and valuation
The DRIFT procedure
Every infant randomised to the DRIFT group received the DRIFT procedure. A full description of the DRIFT
procedure has been published previously.30,45 Given that DRIFT is not currently recommended by NICE
outside research and is not in widespread use, there is no national tariff for this procedure. Therefore, we
used microcosting to estimate the likely cost to NHS hospitals if DRIFT were routinely provided at neonatal
intensive care units (NICUs) with neurosurgical support. The use of some resources will depend on decisions
about where and how to provide the DRIFT procedure. For example, some infants with PHVD would need to
be transported to a NICU with neurosurgical support in order to receive the DRIFT procedure. However, the
same would be true for infants being considered for other neurosurgical procedures (e.g. reservoir or shunt)
as part of standard care. In the RCT, a high proportion of participants were transferred to Bristol from other
hospitals. However, if in routine use at NICUs nationwide, fewer babies would need to be transferred over
shorter distances. In our analysis, we included a cost of transport (£1101 one way46) for every participant
who was transferred from Bristol to an outlying hospital after receiving DRIFT or standard care.
The resources used for the DRIFT procedure and their costs are summarised in Table 24. The amount of
neurosurgical time will depend on whether the neurosurgical team is on-site or needs to travel from a
nearby site. We assumed that neurosurgical support is on-site and, therefore, neurosurgical time to
prepare for, and perform, the procedure would be approximately 2 hours, which includes time to remove
the catheters after DRIFT has concluded. We assumed that, if used in routine practice, the procedure
would be performed on the NICU under intravenous anaesthesia, as happened in the RCT.
The DRIFT procedure itself utilises disposable equipment and a small number of reusable items [i.e. pressure
transducer, IVAC™ pump (Carefusion, Basingstoke, UK)]. Because the reusable equipment is relatively
inexpensive (e.g. IVAC pump ≈£100) and can be reused a large number of times, we assumed that the
proportionate capital cost for each baby is effectively £0. DRIFT uses infusions of artificial CSF, fibrinolytic
and antibacterial drugs to irrigate the ventricles. DRIFT also requires daily microbiology screening of CSF and
frequent monitoring by nursing staff of fluid infusion and drainage, necessitating one-to-one nursing. Some
of these resources (e.g. artificial CSF) are ‘variable’ costs, in that the amount used increases as the number
of days of DRIFT increases. Others (e.g. Alteplase) are ‘fixed’ costs, used only once. DRIFT was typically
conducted for up to 5 days, but could be continued for longer. The number of days of the DRIFT procedure
was extracted from the original trial records and hospital notes where available. Where unavailable, the days
were imputed based on the mean number of days of DRIFT in all participants who received it. The need for
frequent nurse monitoring during DRIFT may increase days on the intensive care unit (ICU) rather than the
high-dependency unit (HDU) or special care unit (SCU). However, many babies would need to be on the ICU
for other care needs. We extracted information on ICU, HDU and SCU days post randomisation (see Initial
Bristol neonatal stay). For the DRIFT RCT, nurses received some training on the DRIFT procedure; we assumed
that, if DRIFT were used routinely, this training would be part of general professional development and
would have negligible incremental costs.
Standard care
Standard care required no intervention unless there was excessive head enlargement or clinical suspicion of
raised intracranial pressure. The standard intervention, if required, was LP, removing 10 ml/kg CSF. Additional
LPs depended on recurrence of these clinical signs. Children in the standard care arm received between zero
and five LPs, with an average of two procedures per baby. However, LPs were also undertaken for children in
the intervention arm both before and after receiving DRIFT. As LP is a cheap and minimally invasive routine
procedure performed by neonatologists on the NICU, we assumed that its costs were bundled in with NICU
day costs.
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TABLE 24 Cost of the DRIFT procedure
Resource Resource type Units
Cost per
unit (£) Cost source
Total
cost (£)
Surgeon time
Neurosurgeon time (hours) Fixed 2 138 Unit Costs of Health and
Social Care 201547
276
Anaesthesia
IV morphine (ampoule) Fixed 1 0.99 British National Formulary48 0.99
IV pancuronium (ampoule) Fixed 1 5.00 British National Formulary48 5.00
Non-reusable equipment
Circuit Fixed 1 66.15 Hospitala 66.15
Collection bags Fixed 3 13.29 Hospitala 39.87
Cannula Fixed 2 51.01 Hospitala 102.02
Three-way taps Fixed 2 0.47 Hospitala 0.94
Syringes Fixed 6 0.06 Hospitala 0.36
Cavilon sticks (3M, Bracknell, UK) Fixed 2 1.29 Hospitala 2.54
Tegaderm dressings
(3M, Bracknell, UK)
Fixed 2 0.22 Hospitala 0.44
Giving set Fixed 3 5.93 Hospitala 17.79
Orange needles Fixed 2 0.01 Hospitala 0.02
Mersilk sutures (Ethicon,
Bridgewater, NJ, USA)
Fixed 4 1.52 Hospitala 6.08
Steristrips (3M, Bracknell, UK) Fixed 2 0.22 Hospitala 0.44
Umbilical cutdown pack Fixed 1 21.90 Hospitala 21.90
Surgeon’s gloves Fixed 1 1.10 Hospitala 1.10
Arterial line Variable p.d. 1 12.92 Hospitala 12.92
Infusions
Alteplase (20 mg vial) (Actilyse;
Boehringer Ingelheim Int.,
Ingelheim, Germany)
Fixed 1 45.00 British National Formulary48 45.00
Artificial CSF part 1 (500 ml) Fixed 1 53.11 Hospitala 53.11
Artificial CSF part 2 (5 mg) Fixed 1 9.20 Hospitala 9.20
Gentamicin (5 mg) (Genticin;
Roche, Basel, Switzerland)
Fixed 1 5.40 Hospitala 5.40
Vancomycin (10 mg) (Vancocin;
Flynn Pharma Ltd, Dublin, Ireland)
Fixed 1 7.70 Hospitala 7.70
Artificial CSF part 1 (500 ml) Variable p.d. 2 53.11 Hospitala 106.22
Artificial CSF part 2 (5 mg) Variable p.d. 2 9.20 Hospitala 18.40
Gentamicin (5 mg) Variable p.d. 2 5.40 Hospitala 10.80
Vancomycin (10 mg) Variable p.d. 2 7.70 Hospitala 15.40
Screening
CSF MCS test Variable 1 8.00 Hospitala 8.00
Total fixed cost (£) 662.09
Total variable cost per day (£) 163.74
MCS, microbiology culture and sensitivity; p.d., per diem.
a North Bristol NHS Trust.
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Subsequent neurosurgical procedures to manage post-haemorrhagic ventricular
dilatation during the initial neonatal stay
In standard care, if LPs failed to drain enough CSF to normalise head growth, a ventricular reservoir was
indicated. If DRIFT was followed by persistent enlargement of ventricles and excessive head growth despite
LPs, a ventricular reservoir was also used. If an infant in either group required repeated reservoir taps to
control head growth, a VP shunt was indicated.32 We used the discharge summary and letter to record
the number of babies who had reservoir or VP shunt procedures during the initial neonatal stay after
randomisation. We used a microcosting approach (Tables 25 and 26) to estimate the cost of these
procedures during the initial neonatal stay.
Initial Bristol neonatal stay
Information on the initial neonatal stay in Bristol was extracted from two complementary sources: (1) the
hospital notes and (2) linked Hospital Episode Statistics (HES) provided by NHS Digital (under data sharing
agreement DARS-NIC-30560-W4V1T-v0.5; Copyright 2016, reused with the permission of The Health &
Social Care Information Centre. All rights reserved). We excluded neonatal days at Bristol or outlying
hospitals prior to randomisation.
TABLE 25 Cost of reservoir
Resource Units Cost per unit (£) Source Total cost (£)
Neurosurgeon A (hours) 1.5 138.00 Unit Costs of Health and
Social Care 201547
207.00
Neurosurgeon B (hours) 1.5 138.00 Unit Costs of Health and
Social Care 201547
207.00
Theatre time (minutes) 180 5.00 Hospitala 900.00
Radio-opaque proximal catheter 1 127.20 Hospitala 127.20
Reservoir (10 mm) 1 223.20 Hospitala 223.20
Total cost (£) 1664.40
a North Bristol NHS Trust.
TABLE 26 Cost of shunt
Resource Units Cost per unit (£) Source Total cost (£)
Neurosurgeon A (hours) 2 138.00 Unit Costs of Health and
Social Care 201547
276.00
Neurosurgeon B (hours) 2 138.00 Unit Costs of Health and
Social Care 201547
276.00
Theatre time (minutes) 150 5.00 Hospitala 750.00
Medium pressure valve (3.5 cm × 1.8 cm) 1 506.40 Hospitala 506.40
Radio-opaque distal catheter 1 454.80 Hospitala 454.80
Radio-opaque proximal catheter 1 127.20 Hospitala 127.20
Disposable catheter passer 1 49.20 Hospitala 49.20
Total cost (£) 2439.60
a North Bristol NHS Trust.
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From Bristol hospital discharge summaries and letters, we extracted the number of days the participant
spent on the ICU, HDU or SCU before discharge home or transfer to an outlying hospital. Hospital services
in Bristol have been reconfigured in the years since the original RCT and a proportion of discharge
summaries and letters were untraceable (10 out of 54, 18.5%). In most cases, the medical notes detailed
the breakdown of stay by ICU/HDU/SCU days but, in some cases, only overall length of NICU stay was
available without a more detailed breakdown. We used data linkage to HES49 data to provide a more
complete picture of the Bristol neonatal stay. HES records care provided to all NHS and privately funded
patients treated in English NHS hospitals. For participants (n = 42) recruited at the Bristol site who survived
and whose parents consented to data linkage, we sent identifiers (date of birth, NHS number, gender and
postcode at birth) to NHS Digital which matched and extracted data on every episode of hospital care. This
included the date of the admission, clinical details (e.g. diagnoses, procedures), length of stay and the
hospital providing the care. HES data did not provide a breakdown of NICU stay by ICU/HDU/SCU days.
After exclusion of pre-randomisation and duplicate episodes, HES data identified 696 episodes of care
provided by 37 different hospitals between birth and 31 March 2016, including at least one episode for all
42 participants for whom linkage was attempted. For the vast majority of episodes (> 99%), there was
an exact match on NHS number, date of birth and gender, indicating that specificity is likely to be high.
In 37 out of 42 (88.1%) participants, HES data identified the initial Bristol neonatal stay, indicating that a
minority of episodes of care were not identified in HES.
In total, 47 out of 54 (87%) participants had data on the initial Bristol neonatal stay: in both HES and
hospital notes (n = 34), in hospital notes alone (n = 10) or in HES alone (n = 3). We used NHS Reference
Costs 2014 to 201546 (Table 27) to cost NICU care. When details were available from the hospital notes,
we used specific costs for each day of ICU, HDU and SCU care. We calculated the mean proportion of all
Bristol NICU days spent on each unit type and used this to impute a weighted daily NICU cost for those
patients for whom only overall NICU length of stay was recorded.
Post-Bristol (transfer) neonatal stay
A high proportion of babies (36 out of 54, 66.7%) were transferred from Bristol to outlying hospitals for
ongoing care after the initial neonatal stay. We requested details of these transfer episodes, including a
breakdown by ICU/HDU/SCU days, from consultants working at these hospitals; however, in some cases
(6 out of 36, 16.7%), no details of the transfer episode could be identified. Again, we used linked HES
data to provide a more complete picture of the transfer neonatal stay for the participants whose parents
consented to data linkage. In total, 35 out of 36 (97%) participants had data on the transfer neonatal
stay: in both HES and hospital notes (n = 15), in hospital notes alone (n = 15) or in HES alone (n = 5).
Piecing together multiple sources of data for Bristol NICU and transfer stays required some judgement, for
example if the discharge date on a discharge summary and HES disagreed. These conflicts were generally
minor and judgements were made while the analyst was blind to randomised allocation.
We used NHS Reference Costs 2014 to 201546 (see Table 27) to cost transfer NICU care. When details
were available from the hospital notes, we used specific costs for each day of ICU, HDU and SCU care.
Preliminary analysis of these notes indicated that a high proportion of transfer NICU care was provided on
TABLE 27 Unit costs of initial hospital stay
Resource Unit cost (£) Source
ICU day 1176.47 NHS Reference Costs 2014 to 201546
HDU day 847.15 NHS Reference Costs 2014 to 201546
SCU day 532.95 NHS Reference Costs 2014 to 201546
Neonatal critical care transportation (one way) 1101.00 NHS Reference Costs 2014 to 201546
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the SCU. Therefore, if details were not available, we multiplied the total NICU days by the cost of a SCU
day. Some babies were transferred to more than one hospital before discharge. For each of these
subsequent transfers, a cost for neonatal critical care transportation was applied.
NHS secondary care post initial neonatal stay
We used linked HES data to identify NHS inpatient and day case care post initial neonatal stay until
31 March 2016 for participants (n = 42) recruited at the Bristol site who survived and whose parents
consented to 10-year follow-up and data linkage. However, six of these participants lived in Wales and an
additional two were known to have emigrated from England soon after birth. Therefore, these analyses
are restricted to the remaining 34 participants. As recruitment took place over a range of years (2003–6),
the duration of follow-up varied by participant from 9.3 years to 13.2 years with a mean of 11.3 years.
Mean duration of follow-up was similar between trial arms (DRIFT 11.2 years, standard care 11.3 years).
Resource use at long-term follow-up
Data on resource use at long-term follow-up were provided by parents completing a questionnaire based
on the CSRI,42 with the assistance of a member of the research team if required. Questions related to
parent(s)’ productivity, child’s education including SEN, child’s outpatient and emergency department (ED)
care in the last 12 months, child’s primary health and social care use and additional expenses incurred
because of the child’s health in the last 6 months. NHS Reference Costs 2014 to 201546 and Unit Costs of
Health and Social Care 201547 (Table 28) were used, where available, to value health and social care.
Parents were asked whether or not their child had attended a special school or special unit in the last
12 months. If the answer was in the affirmative, they were asked to specify whether it was a special unit
within a mainstream school or a special school. If the child attended a special school, parents were asked if
it was a day school or boarding school and if it was government or privately funded. All parents were
TABLE 28 Unit costs of health and social care at 10-year follow-up
Resource Unit cost (£) Source
Outpatient visit 114.50 NHS Reference Costs 2014 to 201546
ED visit 131.92 NHS Reference Costs 2014 to 201546
School nurse 53.70 NHS Reference Costs 2014 to 201546
Health visitor 51.21 NHS Reference Costs 2014 to 201546
Dentist 142.57 NHS Reference Costs 2014 to 201546
GP 44.00 Unit Costs of Health and Social Care 201547
Paediatrician 174.00 Unit Costs of Health and Social Care 201547
Optician 30.00 The College of Optometrists50
Child development centre 46.23 Romeo et al.51
Speech therapist 92.50 NHS Reference Costs 2014 to 201546
Hearing specialist 76.58 NHS Reference Costs 2014 to 201546
Family/individual counselling 90.56 NHS Reference Costs 2014 to 201546
Home help/care worker (1 hour) 24.00 Unit Costs of Health and Social Care 201547
Day centre care (8 hours) 136.00 Unit Costs of Health and Social Care 201547
Social worker (1 hour) 55.00 Unit Costs of Health and Social Care 201547
After-school club 6.00 Assumption
GP, general practitioner.
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also asked whether their child had been given a statement of SEN. We wrote to the schools of all children
recruited in Bristol and consenting to school-age follow-up asking for details on additional funding received
for education and health care plan or statement of SEN. Of 38 schools that responded, 24 confirmed that
they received additional funding. In many cases, the value of funding was not reported; where reported,
it ranged from £5280 to £36,000 with a median of £21,026. Owing to the large number of missing data
on schooling costs, we used published unit costs to differentiate the costs of schooling.
Mainstream schools teaching children with SEN have a notional SEN budget and are expected to meet the
cost of additional support for pupils with SEN up to £6000 per pupil per year.52 This represents a notional
average of SEN costs, with some children requiring more or less support. Official Department for Education
(DfE)53 statistics differentiate between the average total expenditure per pupil per year in a local authority
maintained mainstream secondary school (£6125 in 2014/15) and special schools (£23,078). DfE figures do
not distinguish between special schools and special units in mainstream schools. However, it is likely that
the complexity of needs and, therefore, expenditure per pupil is, on average, lower in special units. We
assumed that the cost of special unit education in a mainstream school was an average of the additional
costs of SEN and special school education (Table 29). We used these DfE figures in our primary analysis.
The cost of special schooling varies considerably depending on the individual needs of the pupil. For
example, a report commissioned by the National Association of Independent Schools and Non-Maintained
Special Schools (NASS)55 estimated that the total annual cost of special education and care varied by 78%,
from £93,711 for day-only education up to £167,268 for 52-week boarding school. The reason for the
large discrepancy between DfE estimates and NASS estimates appears to be that the latter includes
therapy costs, family disability living allowance, equipment, short breaks, travel and facilities costs that are
excluded from the DfE figures. After inclusion of these costs, the NASS report concluded that costs at
independent special schools are similar to those at equivalent local authority maintained special schools.
Therefore, in sensitivity analyses (see Table 29), we use NASS figures to estimate the unit costs of
education and educational care in special schools.
Parents/carers were asked if they were currently employed and, if so, how many hours they worked on
average per week. They were also asked to provide the same information for their partner, if applicable.
We used this to estimate the household hours worked per week. We used Annual Survey of Hours and
Earnings: 2015 Provisional Results54 mean gross pay per hour to estimate household weekly income from
employment (see Table 29). This will not detect any impact of child health on the type of employment that
the parents/carers are willing and able to take up. Therefore, we asked a supplemental question about
whether the main source of household was from earned income or benefits to get a better overview of
household income.
TABLE 29 Unit costs of productivity and schooling at 10-year follow-up
Resource Unit cost (£) Source
Productivity (hourly gross pay) 15.70 Annual Survey of Hours and
Earnings: 2015 Provisional Results54
Mainstream school (per year) 6125 DfE53
Additional cost of SEN education in mainstream school (per year) 6000 Education Funding Agency52
Special unit, mainstream school (per year) 17,601 Assumption
Special school (per year) 23,078 DfE53
93,711a Clifford and Theobold55
a Figure used in sensitivity analysis.
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Although HES data sets on outpatient (from 2003) and ED (from 2007) care are available, we focused
exclusively on HES data on day case and inpatient care. Outpatient and ED data sets were designated as
‘experimental’ statistics at the start of the DRIFT follow-up period. Our decision was based on the high cost
of acquiring linked data and probable lower cost and impact on our conclusions of NHS outpatient and ED
care. A snapshot of emergency, outpatient and other community care not captured by HES was elicited
from parents at the 10-year follow-up (see Resource use at long-term follow-up).
Hospital stays with multiple episodes of care were concatenated and the dominant Healthcare Resource
Group (HRG) code was used to estimate the cost of care. HRGs, which group clinically similar admissions
requiring similar levels of resources, are the basis of hospital reimbursements for care provided. As care
occurred over a period of > 10 years, several different versions of HRG codes were recorded. We applied
the most recent available NHS Reference Costs 2014 to 201546 for the HRG and, where necessary, inflated
the cost to 2014/15 values assuming 2.5% inflation per annum.56 Based on data on admission type and
length of stay, each admission was classified as a ‘day case’, ‘elective long stay’, ‘non elective short stay’
or ‘non elective long stay’, as reference costs vary by admission type. In some cases, hospitals receive
additional reimbursements if patients spend an unexpectedly long time in hospital [excess bed-day (EBD)].
For each HRG, we calculated the trim point (the days after which EBD payments apply) and, for patients
whose hospital stay exceeded the trim point, estimated the EBD cost based on the national EBD reference
cost for that HRG. All costs of care occurring after the first year of life were discounted at 3.5% per
annum in line with NICE guidance.57
Health-related quality of life
In addition to the cognitive, functional and other outcomes described in earlier sections of this report,
parents were also asked to complete two generic measures of their child’s health-related QoL (HRQoL)
at the 10-year follow-up. The measures, the Health Utilities Index – 3 (HUI3)58,59 and the EuroQol-5
Dimensions (EQ-5D), five-level version (EQ-5D-5L),60 are preference-based measures, which produce
a single ‘utility’ score anchored at best possible HRQoL (score 1) and HRQoL equivalent to death
(score 0). We selected the HUI3 [covering eight attributes: (1) vision, (2) hearing, (3) speech, (4) emotion,
(5) pain, (6) ambulation, (7) dexterity and (8) cognition] to allow direct comparison with previous work
in neurodevelopmental disability in childhood.61 We selected the EQ-5D-5L [covering five attributes:
(1) mobility, (2) self-care, (3) usual activities, (4) pain/discomfort and (5) anxiety/depression] as it is
commonly used in the UK by NICE57 to judge the cost-effectiveness of new medical technologies.
A youth version of the EQ-5D [EuroQol-5 Dimensions – Youth (EQ-5D-Y)] is now available with modified
age-appropriate language for self-completion by children aged 7–12 years. However, owing to the
prevalence of cognitive impairment and CP, parents completed the questionnaire on behalf of their child.
As the EQ-5D-5L measures five levels on each attribute (rather than three levels in the EQ-5D-Y), we chose
the EQ-5D-5L as potentially more sensitive to differences in participants’ QoL. The EQ-5D also includes a
visual analogue scale (VAS) that parents can use to rate their child’s health today on a scale from 0
(worst health imaginable) to 100 (best health imaginable).
The UK adult value set62 was employed to estimate the EQ-5D-5L utility score; for the HUI3 scores, the
multiattribute health status classification system was used.59 Both the HUI3 and the EQ-5D-5L are designed
to be used prior to randomisation, and at repeated intervals post randomisation, to calculate quality-
adjusted life-years (QALYs). In the UK, NICE favours QALYs when comparing the cost-effectiveness of
different medical technologies within, and between, different patient populations. In our primary analysis,
we report the mean score among survivors completing the questionnaire at the 10-year follow-up. In
sensitivity analyses, we also present mean scores after including, with a score of zero, participants known
to have died before 10-year follow-up.
Decision analysis model methods
We developed a simple decision analytical model to estimate the cost-effectiveness (cost per QALY) of
DRIFT compared with standard care from birth to age 18 years. The primary perspective was that of NHS
and Personal Social Services in accordance with NICE guidance.57 In secondary analysis, we broaden the
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perspective to include education costs. We initially planned a discrete health state Markov model stratifying
children by the degree of disability and survival (none, mild, moderate, severe, dead), such as that outlined
by Petrou and Khan.18 In such a model, each health state would be assigned a cost representing the costs
of care and a utility score representing the impact on the individual’s HRQoL. However, the small sample
size and infrequent follow-up in the DRIFT study meant that we could not reliably estimate transition
probabilities between health states of a discrete health state model.
Therefore, we developed a simple two-state (alive or dead) Markov cohort decision model with a 1-year
cycle length based on parameters derived directly from DRIFT trial data among participants recruited at
Bristol. To estimate costs and health benefits, we assumed that transitions between health states occur
halfway through each cycle (i.e. a half-cycle correction). We used a 3.5% annual discount rate for both
costs and QALYs. The following model parameters, stratified by trial arm, were derived from DRIFT trial
data: (1) cost of DRIFT (microcosting), (2) cost of remainder of NICU stay (hospital notes and HES data),
(3) cost of postnatal inpatient care from age 0 to 2 years (HES data), (4) cost of postnatal inpatient care
from age 2 to 10 years (HES data), (5) mortality from age 0 to 2 years (trial follow-up), (6) mortality
from age 2 to 10 years (trial follow-up), (7) EQ-5D-5L index scores at 10-year follow-up (parent report),
(8) 12-month cost of ambulatory hospital care at 10-year follow-up (parent report), and (9) 6-month cost
of primary and community care at 10-year follow-up (parent report). We assigned probability distributions
to all these stochastic parameters. Where cost and mortality rate parameters span > 1 year (e.g. postnatal
inpatient cost or mortality from age 2 to 10 years) or < 1 year (e.g. primary and community care), we
annualised and made the simplifying assumption that these costs and rates were constant across the years.
We provide more detail on these parameters and their probability distributions in Results.
Inevitably, a model based on scant data requires a number of large assumptions. We made the following
key assumptions in the model: (1) mortality between age 10 and 18 years is zero in both arms of the
trial; (2) the EQ-5D-5L scores observed among survivors at 10-year follow-up are representative of scores
among survivors at all ages; (3) the costs of education observed among survivors at 10-year follow-up
are representative of these costs among all school ages (4–18 years) survivors; (4) the ambulatory- and
community care costs observed among survivors at 10-year follow-up are representative of costs among
survivors at all ages; and (5) we used the results of the unadjusted analyses comparing costs and outcomes
between DRIFT and standard care. We tested the sensitivity of our model findings to some of these key
assumptions.
Analysis
Primary economic evaluation: within-trial cost–consequence analysis
A cost–consequence analysis was conducted to compare the costs and effects of DRIFT with standard care.
The analysis included neonatal stay costs, NHS secondary care costs up to 31 March 2016 and a snapshot
of broader NHS costs, social care costs, educational costs, family expenses and productivity losses at
10 years’ follow-up. Participants were analysed according to the treatment group to which they were
randomised (i.e. an ITT approach) and we report on all available cases for each analysis.
Mean resource use and mean costs per patient were estimated in both trial arms. Regressions using
ordinary least squares (OLS) and a general linear model (GLM) using a gamma family and log-link were
employed to obtain the differences in mean costs between DRIFT and standard care arms. Gamma log-link
GLM is commonly used to analyse small samples of skewed cost data (i.e. high-cost outliers).63 As the point
estimates and CIs were similar between OLS and GLM models, we present only the OLS results. Logistic
regression was used to evaluate differences in binary outcomes. In line with the primary outcome analysis,
results are presented ‘unadjusted’ and ‘adjusted’ for the baseline covariates: grade of IVH, birthweight and
gender. Stata 14.1 was used for all health economic analyses.
DOI: 10.3310/hta23040 HEALTH TECHNOLOGY ASSESSMENT 2019 VOL. 23 NO. 4
© Queen’s Printer and Controller of HMSO 2019. This work was produced by Luyt et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
53
Sensitivity analyses
We conducted the following sensitivity analyses to test the robustness of our primary analyses to
different assumptions:
l using NASS costs of special education, which include health and social care needs while at special
school, to provide a less conservative estimate than the DfE figures
l imputing EQ-5D-5L scores of zero for participants known to have died before 10-year follow-up
l no discounting of costs that occur in the years after birth.
Secondary economic evaluation: decision analysis model
The results of the model were summarised using incremental cost-effectiveness ratios (ICERs), the
incremental net monetary benefit (INMB) statistic and cost-effectiveness acceptability curves.64 We used
the model to judge the probability that DRIFT is cost-effective at age 18 years against the NICE threshold
of £20,000 to £30,000 per QALY. In our analyses, we used the lower figure (λ = £20,000) in calculating
INMB. We conducted a probabilistic sensitivity analysis to quantify uncertainty about the cost-effectiveness
of DRIFT. Monte Carlo simulation was used to repeatedly draw a randomly selected estimate of each model
parameter from its estimated distribution. We used a conventional number of iterations (n = 10,000) to
empirically estimate the uncertainty surrounding the mean INMBs calculated from the model. The model
was built in Microsoft Excel® (Microsoft Corporation, Redmond, WA, USA) and programmed in Visual Basic
for Applications® (Microsoft Corporation, Redmond, WA, USA) to run the simulation.
Because of the number of large assumptions required to estimate cost per QALY, we consider the results
of the decision analysis model to be exploratory. We used deterministic sensitivity analyses to test the
impact of the following key assumptions on the findings of the model.
l estimating costs and outcomes at age 10 years rather than age 18 years
l using costs and utility scores adjusted for baseline covariate, gender, IVH grade and birthweight
l including educational costs
l using HUI3 rather than EQ-5D-5L utility scores.
Results
Participants included in the economic analyses
The numbers of participants with data available for each analysis differ (see Figure 24). Participants included
in the analysis of initial neonatal costs were relatively similar to all participants recruited in Bristol in terms
of birthweight, IVH grade 4 and gender (Table 30). However, participants included in the post-neonatal
hospital cost and 10-year follow-up analyses tended to have a higher birthweight and were less likely to
have grade 4 IVH. This is unsurprising given that these participants are survivors. The imbalance between
DRIFT and standard care participants in terms of birthweight and gender widened slightly among
participants included in the post-neonatal hospital cost and 10-year follow-up analyses.
Initial hospitalisation
Participants allocated to DRIFT had irrigation therapy for an average of 5.2 days at an estimated cost of
£1513 per participant (Table 31). Some of this initial cost of DRIFT was offset by the fact that fewer patients
had reservoir procedures during the neonatal stay. Participants allocated to DRIFT tended to spend fewer
days in the Bristol NICU (mean 29.8 days) than participants allocated to standard care (mean 40.3 days).
In contrast, participants allocated to DRIFT tended to stay longer in outlying hospitals (mean 38.5 days)
after transfer from the Bristol NICU than participants allocated to standard care (mean 18.2 days). The total
mean costs of the neonatal stay were higher in patients who had DRIFT, but the CI was wide and included
zero (unadjusted mean difference £6556, 95% CI –£11,161 to £24,273). The finding was sensitive to
adjustment for covariates, particularly birthweight. After adjustment for birthweight, gender and IVH grade,
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estimated mean costs of neonatal care were lower in patients who had DRIFT although CIs were still wide
and included zero (adjusted mean difference –£3056, 95% CI –£19,449 to £13,335).
Postnatal hospital admissions and total NHS secondary care costs
Participants allocated to DRIFT spent an average of 19.4 days in hospital up to age 2 years and an average
of 26.6 additional days in hospital between age 2 years and 31 March 2016 (see Table 31). Participants
allocated to standard care spent fewer days in hospital than participants allocated to DRIFT (8.8 days,
0–2 years; 18.5 days, 2 years onwards; see Table 31). The most common HRG chapters for postnatal admission
episodes were ‘Diseases of childhood’ (335 out of 573; 58.5%), ‘Nervous system’ (71 out of 573; 12.4%),
‘Mouth, head, neck and ears’ (34 out of 573; 5.9%) and ‘musculoskeletal system’ (31 out of 573; 5.4%).
The unadjusted total costs of hospital care after the initial neonatal stay were higher in participants
allocated to DRIFT (unadjusted mean difference £3413, 95% CI –£12,408 to £19,234). This finding was
very sensitive to adjustment for covariates, particularly gender and birthweight. After adjustment, the
estimated mean cost among participants allocated to DRIFT was lower (adjusted mean difference –£9739,
95% CI –£27,558 to £8080). In sensitivity analysis 3, the adjusted mean cost difference was somewhat
larger if costs were not discounted (adjusted mean difference –£12,348, 95% CI –£33,603 to £8907).
TABLE 30 Cases available for economic analysis
Case characteristics
Trial arm
DRIFT Standard care
N N
All Bristol participants 27 27
Birthweight, mean (SD) 1045 (332) 1285 (502)
Gestation, weeks (SD) 27.2 (2.5) 28.0 (2.8)
IVH grade 4, n (%) 12 (44) 14 (52)
Male, n (%) 23 (85) 18 (67)
Initial neonatal and transfer costs 24 23
Birthweight, mean (SD) 1059 (345) 1273 (518)
Gestation, weeks (SD) 27.3 (2.6) 28.0 (2.9)
IVH grade 4, n (%) 11 (46) 11 (48)
Male, n (%) 20 (83) 15 (65)
Post-neonatal hospital costs 18 16
Birthweight, mean (SD) 1073 (346) 1375 (577)
Gestation, weeks (SD) 27.4 (2.5) 28.7 (2.9)
IVH grade 4, n (%) 8 (44) 5 (31)
Male, n (%) 18 (100) 9 (56)
10-year QoL and resource use 23 17
Birthweight, mean (SD) 1074 (345) 1353 (568)
Gestation, weeks (SD) 27.5 (2.6) 28.5 (2.9)
IVH grade 4, n (%) 10 (43) 7 (41)
Male, n (%) 20 (87) 10 (59)
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TABLE 31 Cost of neonatal and postnatal secondary care, by trial arm
Secondary care
Trial arm
Difference in mean costs, £ (95% CI)DRIFT Standard care
n
Mean (SD)
units
Mean (SD)
costs, £ n
Mean (SD)
units
Mean (SD)
costs, £ Unadjusted Adjusteda
DRIFT 24 5.2 (1.7) days 1513 (276)
Reservoir during NICU stay 24 0.54 (0.51)b
procedures
902 (847) 23 1.0 (0.30)b
procedures
1664 (502)
VP shunts during NICU stay 24 0.25 (0.44)b
procedures
610 (1080) 23 0.26 (0.45)b
procedures
636 (1095)
Bristol NICU stay 24 29.8 (27.3) days 26,850 (22,367) 23 40.3 (42.5) days 33,150 (35,474)
Transfer NICU stay 27 38.5 (52.1) days 31,489 (34,705) 26 18.2 (26.5) days 15,382 (19,538)
Subtotal neonatal costs 24 59,395 (29,411) 23 52,839 (30,820) 6556 (–11,161 to 24,273) –3056 (–19,449 to 13,335)
Postnatal admissions (0–2 years) 18 19.4 (26.1) days 8768 (9021) 16 8.8 (10.4) days 5732 (8053)
Postnatal admissions (2 years
onward)
18 26.6 (63.8) days 15,293 (21,118) 16 18.5 (21.5) days 14,907 (19,116)
Subtotal postnatal discounted
costs
18 24,051 (22,540) 16 20,638 (22,679) 3413 (–12,408 to 19,234) –9739 (–27,558 to 8080)
Total NHS inpatient costs 18 86,893 (39,829) 16 75,009 (44,274) 11,884 (–17,491 to 41,259) –20,963 (–49,213 to 7269)
a Adjusted by gender, IVH grade and birthweight.
b Only those patients who had the procedure during the initial neonatal or transfer stay. Some patients had these procedures during readmissions. The costs of these readmission
procedures are captured under postnatal admissions.
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Total unadjusted NHS inpatient costs since birth were higher in participants allocated to DRIFT (unadjusted
mean difference £11,884, 95% CI –£17,491 to £41,259). Again, this finding was very sensitive to
adjustment for birthweight and gender (adjusted mean difference –£20,963, 95% CI –£49,213 to £7269).
Use of ambulatory health and social care at ten-year follow-up
There was little evidence of a difference in emergency and outpatient care in the last 12 months at the
10-year follow-up (Table 32). Parents of participants in both arms of the trial reported an average of just
over 0.4 visits to the ED and just over 2.8 outpatient clinic visits. The adjusted difference in mean costs was
marginally higher in participants allocated to DRIFT (adjusted mean difference £2, 95% CI –£264 to £267).
The costs of other ambulatory care during the last 6 months were higher in participants randomised to
standard care (adjusted mean difference –£108, 95% CI –£596 to £380), but the CI was wide. In free text,
parents of participants in both arms noted a wide range of other therapies including orthotics, physiotherapy,
occupational therapy, hydrotherapy and music therapy, although the frequency of these therapies was often
not recorded.
Family income, expenses and child’s educational needs
Overall, a similar proportion of parents/carers were employed at the 10-year follow-up (Table 33). Including
22 cases where a partner’s employment status was also reported, 68% (23 out of 34) of parents/carers of
DRIFT participants were employed and 64% (18 out of 28) of parents/carers of standard care participants
were employed. The average working hours were 36.9 in the households of participants who received
DRIFT (estimated weekly income of £580), compared with 38.1 (estimated weekly income of £599) in the
households of participants who received standard care. However, a lower proportion of households of
participants who received DRIFT had benefits as their main source of income (adjusted OR 0.23, 95% CI
0.04 to 1.22), although the CI included 1.
A similar percentage of parents of participants in both arms reported that their child had a SEN statement
(see Table 33). However, a higher percentage of parents of participants in the standard care arm reported
that their child attended a special unit or special school (adjusted OR 0.13, 95% CI 0.02 to 0.82). Owing
to the high cost of special schooling, this is potentially economically important; the adjusted mean
difference in estimated annual school costs was –£5321, 95% CI –£9772 to –£870. In sensitivity analyses,
if higher NASS estimates of the costs of special schooling are used, the adjusted difference in estimated
school costs becomes much higher –£35,122, 95% CI –£58,546 to –£11,699. Other family expenses
reported by parents in free text included equine therapy, nappies, play equipment, transport, wheelchair
equipment and insurance and home modifications.
Child’s health-related quality of life
In adjusted analyses, both the EQ-5D-5L and HUI3 scores of HRQoL tended to be higher in survivors who
were allocated to DRIFT than in those who were allocated to standard care (Table 34). However, the CIs
around the adjusted mean differences in EQ-5D-5L score (0.06, 95% CI –0.11 to 0.22) and HUI3 score
(0.13, 95% CI –0.09 to 0.35) included zero. Imputing a score of zero for the six children recruited in
Bristol who were known to have died (two in the DRIFT arm, four in the standard care arm) led to similar
conclusions: adjusted mean differences in EQ-5D-5L score (0.10, 95% CI –0.08 to 0.29) and HUI3 score
(0.13, 95% CI –0.07 to 0.33). In contrast, EQ-5D-5L VAS scores were higher in participants allocated to
receive standard care (adjusted mean difference –11.18, 95% CI –23.66 to 1.32).
Associations between cognitive status, quality of life and total NHS costs
We observed the expected positive correlation between better cognitive status at 10-year follow-up and
higher QoL scores as measured by the HUI3 and EQ-5D-5L (Figures 25–28). The QoL scores ranged across
almost the entire spectrum of scores on the HUI3 and EQ-5D-5L (see Table 34). The EQ-5D-5L VAS was
an exception, showing a high ceiling effect (many scores of 1) and no evident correlation with cognitive
status. We also observed the expected negative correlation between cognitive status at 10-year follow-up
and NHS inpatient care costs over the child’s lifetime.
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TABLE 32 Child’s ambulatory health and social care use at school age, by trial arm
Visits (in the last)
Trial arm
Difference in mean costs, £ (95% CI)DRIFT Standard care
n
Mean (SD)
units
Mean (SD)
costs, £ n
Mean (SD)
units
Mean (SD)
costs, £ Unadjusted Adjusteda
ED (12 months) 23 0.43 (0.59) 17 0.41 (0.62)
OP (12 months) 23 2.83 (3.05) 17 2.82 (2.96)
Total ambulatory hospital care (12 months) 23 381 (382) 17 378 (360) 3 (–238 to 244) 2 (–264 to 267)
GP (6 months) 23 1.70 (1.94) 17 1.12 (1.32)
Optician (6 months) 23 0.57 (0.66) 17 1.23 (1.03)
Dentist (6 months) 23 1.13 (0.69) 17 1.29 (0.77)
Paediatrician (6 months) 23 0.43 (0.66) 17 0.76 (0.75)
Speech therapist (6 months) 23 1.52 (4.25) 17 1.76 (4.85)
Hearing specialist (6 months) 23 0.30 (0.56) 17 0.35 (0.61)
School nurse (6 months) 23 0.65 (2.50) 17 2.24 (4.94)
Individual counselling (6 months) 23 0.26 (1.25) 17 0.71 (2.91)
Social worker (6 months) 23 0.48 (1.08) 17 0.94 (1.98)
Otherb ambulatory care (6 months) 23 14.26 (28.87) 17 1.94 (3.47)
Total ambulatory community care (6 months) 23 569 (626) 17 718 (736) –148 (–586 to 287) –108 (–596 to 380)
a Adjusted by gender, IVH grade and birthweight.
b Health visitor, child development centre, family counselling, home help, day centre, after-school club. The large mean in the DRIFT group is due to a small number of individuals reporting
a high number of after-school club visits and home help.
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TABLE 33 Family income and child’s educational needs
Income and
educational needs n DRIFT n
Standard
care
Unadjusted
(95% CI)
Adjusteda
(95% CI)
First parent/carer
employed
23 16 out of 23
(70%)
17 9 out of 17
(53%)
OR 2.03
(0.55 to 7.47)
OR 1.55
(0.36 to 6.75)
Partner employedb 11 7 out of 11
(64%)
11 9 out of 11
(82%)
OR 0.39
(0.05 to 2.77)
OR 0.60
(0.04 to 9.31)
Estimated weekly
household income from
employment
23 £580 17 £599 –£19
(–£287 to £325)
£0
(–£325 to £325)
Main source of income
is benefits
23 4 out of 23
(17%)
17 7 out of 17
(41%)
OR 0.30
(0.07 to 1.28)
OR 0.23
(0.04 to 1.22)
Child has SEN statement 23 13 out of 23
(57%)
17 10 out of 17
(59%)
OR 0.91
(0.26 to 3.24)
OR 0.41
(0.08 to 2.10)
Child attends special
unit/school
23 5 out of 23
(22%)
17 7 out of 17
(41%)
OR 0.40
(0.10 to 1.58)
OR 0.13
(0.02 to 0.82)
Estimated annual cost of
schooling
23 £11,659 17 £14,164 –£2505
(–£7067 to £2056)
–£5321
(–£9772 to –£870)
Estimated annual cost of
schooling SA1
23 £23,943 17 £43,249 –£19,305
(–£43,755 to £5144)
–£35,122 (–£58,546
to –£11,699)
a Adjusted by gender, IVH grade and birthweight.
b Twenty-two parents/carers provided information on their partner.
TABLE 34 Child’s HRQoL
HRQoL
Trial arm
Difference in mean score (95% CI)DRIFT Standard care
n
Mean (SD)
score n
Mean (SD)
score Unadjusted Adjusteda
EQ-5D-5L index score 23 0.70 (0.25) 18 0.70 (0.31) 0.00 (–0.18 to 0.17) 0.06 (–0.11 to 0.22)
EQ-5D-5L index score (SA2)b 25 0.64 (0.31) 22 0.57 (0.39) 0.07 (–0.14 to 0.27) 0.10 (–0.08 to 0.29)
HUI-3 index score 23 0.53 (0.34) 18 0.49 (0.43) 0.04 (–0.21 to 0.28) 0.13 (–0.09 to 0.35)
HUI-3 index score (SA2)b 25 0.49 (0.35) 22 0.40 (0.43) 0.08 (–0.14 to 0.31) 0.13 (–0.07 to 0.33)
EQ-5D-5L VAS score 23 78.6 (19.9) 18 90.8 (15.1) –12.22 (–23.66 to –0.79) –11.18 (–23.66 to 1.32)
a Adjusted by gender, IVH grade and birthweight.
b Including a score of zero for participants known to have died.
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FIGURE 27 Association between cognition and inpatient costs.
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FIGURE 25 Association between cognition and EQ-5D-5L.
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Results of the decision analytical model
The parameters used to estimate the model are presented in Table 35. The results of this exploratory
analysis (Table 36) indicate that DRIFT has the potential to be a cost-effective intervention at current NICE
thresholds. At 18 years, the additional benefit (8.96 QALYs vs. 8.33 QALYs) resulting primarily from the
lower mortality in the DRIFT arm justifies the higher NHS and social service costs (£112,341 vs. £102,611).
The ICER (£15,621) is below the NICE thresholds of £20,000 to £30,000 per QALY and the INMB (£2711)
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FIGURE 28 Association between cognition and EQ-5D-5L VAS.
TABLE 35 Parameters of the decision analytical model derived from the DRIFT data
Parameter Value Distribution Parametersa
Cost of DRIFT (£) 1513 Log-normal 7.32 0.04
Cost of NICU stay (DRIFT) (£) 57,882 Log-normal 10.96 0.10
Cost of NICU stay (SC) (£) 52,839 Log-normal 10.87 0.12
Postnatal inpatient cost 0_2 (DRIFT) (£) 8876 Log-normal 9.06 0.24
Postnatal inpatient cost 0_2 (SC) (£) 5790 Log-normal 8.61 0.34
Postnatal inpatient cost 2_10 (DRIFT) (£) 18,209 Log-normal 9.76 0.32
Postnatal inpatient cost 2_10 (SC) (£) 18,245 Log-normal 9.76 0.31
Ambulatory care cost 12 months (DRIFT) (£) 381 Log-normal 5.92 0.21
Ambulatory care cost 12 months (SC) (£) 378 Log-normal 5.91 0.23
Community care cost 6 months (DRIFT) (£) 569 Log-normal 6.32 0.23
Community care cost 6 months (SC) (£) 718 Log-normal 6.55 0.24
EQ5D-5L decrement (DRIFT) 0.3031 Log-normal –1.21 0.17
EQ5D-5L decrement (SC) 0.2983 Log-normal –1.24 0.24
Mortality rate 0_2 (DRIFT) 0.0370 Beta 1.00 26.00
Mortality rate 0_2 (SC) 0.1111 Beta 3.00 24.00
Mortality rate 2 to 10 (DRIFT) 0.0417 Beta 1.00 23.00
Mortality rate 2 to 10 (SC) 0.0500 Beta 1.00 19.00
SC, standard care.
a For lognormal distributions, these are the mean of ln (x) and the SD of ln (x). For beta distributions, these are the alpha
and beta parameters.
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is positive. However, there is a high degree of uncertainty about the effect of DRIFT on both the costs
and outcomes of care, as indicated by the very wide CI surrounding the INMB estimate and the flat
cost-effectiveness acceptability curve, which shows that DRIFT has close to 0.5 probability of being
cost-effective (Figure 29). However, in scenarios in which education costs (see Table 36, MSA3) are
included or using costs and utility scores adjusting for gender, IVH grade and birthweight (see Table 36,
MSA2), DRIFT has the potential to both save money and improve outcomes for children. In both scenarios,
there is a high probability (> 0.75) that DRIFT is cost-effective at NICE thresholds.
Discussion
Main findings
We found no evidence that the DRIFT intervention either increased or decreased the cost of the initial
neonatal stay. The initial cost of DRIFT was offset, to an extent, by the fact that fewer procedures to insert
reservoirs were carried out. However, the costs of these procedures were small in comparison with the
overall costs of NICU care. There was high between-patient variation in NICU length of stay and, therefore,
in the costs of NICU care. We observed differences between trial arms in the distribution of NICU stay.
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FIGURE 29 Cost-effectiveness acceptability curve.
TABLE 36 Cost-effectiveness results from the decision analytical model
Decision analytical
model
Trial arm
ICER (£) INMB (£)b (95% CI)c
DRIFT Standard care
Costa (£) QALYsa Costa (£) QALYsa
Primary analysis 112,341 8.9566 102,611 8.3338 15,621 2711 (–52,397 to 58,445)
MSA1 94,677 5.7128 85,172 5.3452 25,856 –2152 (–39,195 to 36,015)
MSA2 98,833 9.3089 116,571 7.9178 DRIFT
dominant
45,558 (–6289 to 97,203)
MSA3 219,182 8.9566 232,409 8.3338 DRIFT
dominant
25,684 (–43,690 to 97,313)
MSA4 112,341 6.7946 102,611 5.8534 10,338 9095 (–57,309 to 78,277)
a Deterministic analysis, discounted values.
b At a willingness to pay threshold of £20,000 per QALY.
c Probabilistic analysis, discounted values.
MSA1, estimating costs and outcomes at age 10 years rather than age 18 years; MSA2, using costs and utility scores
adjusted for baseline covariate, gender, IVH grade and birthweight; MSA3, including educational costs; MSA4, using HUI3
rather than EQ-5D-5L utility scores.
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Participants who received DRIFT spent fewer days in the Bristol NICU but more days in other NICUs after
transfer from Bristol. It is possible that the lower number of reservoir procedures after DRIFT allowed these
babies to be transferred back to the outlying NICU more quickly without decreasing total NICU stay.
In adjusted analyses, we estimated that DRIFT might reduce the costs of neonatal care by approximately
£3000, but the wide CI means that we cannot rule out the possibility that it increases costs.
In a subgroup (34 out of 54; 63%) of patients who survived to the 10-year follow-up, who lived in
England and whose parents consented to data linkage, unadjusted analyses suggested that those who
received the DRIFT intervention spent slightly more days in hospital after the initial neonatal stay. There
was no strong evidence that the DRIFT intervention increased or decreased the costs of postnatal inpatient
care or total NHS inpatient costs. The finding in unadjusted analyses that total costs of inpatient care were
approximately £11,800 higher in participants who received DRIFT was very sensitive to adjustment for
birthweight and gender. After adjustment, costs in the DRIFT arm were estimated to be approximately
£21,000 lower. These findings should be interpreted cautiously owing to the sensitivity of the estimates,
the wide CIs and the selective nature of the subgroup. It is worth noting that babies in the DRIFT arm
included in the analysis of postnatal costs were less mature (on average 300 g smaller and born 1 week
earlier) than those in the standard care arm. Therefore, other comorbidities due to immaturity at birth may
have affected readmissions to hospital during childhood.
A subgroup of parents (41 out of 54; 76%) reported on QoL, recent health and social care, employment
and educational needs. Children had wide-ranging health and social care needs at the 10-year follow-up;
however, there was no evidence of economically important differences between participants who received
DRIFT and those who received standard care. There was no evidence that DRIFT had an impact on household
income, although there was a non-significant trend for a lower proportion of households of participants who
received DRIFT to report having benefits as their main source of income. A lower proportion of parents of
children in the DRIFT arm reported that their children attended a special school or unit. Because of the high
costs and likelihood of ongoing need of special education, the potential savings (approximately £2550 and
£5300 per annum in unadjusted and adjusted analysis, respectively) are likely to be very influential in the
economic case for DRIFT; it is likely to become more cost-effective over the future lifetime of survivors.
There was no evidence of differences in QoL scores (HUI3 and EQ-5D-5L) at 10-year follow-up between
participants who received DRIFT and those who received standard care. The EQ-5D-5L VAS was higher
(better) among participants who received standard care; however, this measure showed no correlation
with the primary outcome of cognitive function. Previous work65 has demonstrated that the EQ-5D-5L is
more strongly correlated than the EQ-5D-5L VAS with disease-specific measures of QoL. It is also unclear
how parents of children with lifelong cognitive and other health problems would interpret the VAS end point
labels of ‘best/worst health you can imagine’. For these reasons, we believe that the EQ-5D-5L and HUI3 are
likely to be more valid indicators of patient outcomes in this population.
Exploratory analysis using a simulation model to interpolate and extrapolate costs and outcomes to age
18 years indicated that DRIFT has the potential to be cost-effective at conventional willingness-to-pay
thresholds used by the NHS. In some scenarios (including education costs and using adjusted estimates
of costs and outcomes), DRIFT was very likely to be cost-effective and might both save money and
improve outcomes.
Strengths and weaknesses
We have provided the first evidence on the cost-effectiveness of the DRIFT procedure for infants with
PHVD. The evidence is drawn from a RCT study design, which minimises the risk of selection bias. The
long-term follow-up obtained in a high proportion of participants enabled us to compare the ongoing
educational, health and social care needs of children. Our economic analysis is limited by a small sample
size and in being restricted to one NICU. In microcosting the DRIFT intervention, we used unit costs derived
from one hospital. Unit costs for the DRIFT intervention will vary somewhat from hospital to hospital;
however, given the high cost of NICU and subsequent care, this variation is not likely to be pivotal in
determining the cost-effectiveness of DRIFT.
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Owing to the huge variance in health-care needs and costs of participants, a much larger trial would be
needed to provide greater certainty about whether DRIFT increases or decreases NHS costs and other costs
in the long term. Small RCTs are vulnerable to imbalances in important baseline covariates.66 This was the
case for birthweight and gender in this trial, which resulted in some of our findings being very sensitive
to adjustment for these covariates. In the case of outcomes which were measured in only a subset of
survivors, such as the cost of postnatal care, it is unclear whether or not the unadjusted analysis, which
ignores baseline imbalances, or adjusted analysis, which may exacerbate attrition bias, will be more
accurate. The data are not missing completely at random. We do not have postnatal cost data for the
participants who died or for those who did not live in England, one of whom, in the standard care arm,
was known to require permanent residential medical care.
Another challenge was the retrospective nature of several elements of the evaluation. As the original RCT
had not included an economic evaluation, we were reliant on hospital notes being available and accurately
recording relevant details. We were able to extract details on the Bristol NICU and any transfer NICU stay
for most participants and supplemented this with HES data. However, no information on the Bristol NICU
stay was available for some patients (7 out of 54; 13%) and they were excluded from the analysis; in other
patients, some details (e.g. HDU days) had to be imputed. Other important elements of the economic
evaluation, for example QoL between birth and school age, were also unavailable. Owing to the
incomplete information, we chose to report a cost–consequence study based on available cases as our
primary analysis rather than a more conventional cost-effectiveness analysis.
Our study illustrates the strengths and weaknesses of HES data for economic evaluation. Acquiring HES
data involved a lengthy process of approval. However, without HES, we could not have built up such a
detailed picture of inpatient care during the first 10 years of life. Parent recall would probably have been
inaccurate over such a long period of time and it would have been impractical to identify all hospitals
where care had been provided in order to extract data from notes. However, we had consent for data
linkage from only 42 out of 54 (78%) parents and, as a number of families lived in Wales or emigrated,
HES data were not comprehensive. Recent work67 concluded that HES birth data offer a high-quality data
set that captures the majority of English hospital births. We found that linked HES data had high, but not
perfect, sensitivity for identifying the Bristol NICU episode and excellent specificity. It is unclear whether the
absence of linked HES birth data is a failure of linkage (e.g. inaccurate record of date of birth and NHS
number) or of absence of the episode from the HES data set. However, the imperfect sensitivity of data
linkage suggests that our estimate of postnatal inpatient costs is likely to be conservative.
Accurate measurement of health and social care use is difficult in a group of children with such wide-ranging
needs. We asked parents to quantify their child’s use of a wide variety of professionals and services. However,
the relatively large number of free-text comments, often without enough details to estimate costs, indicated
that our estimate of ambulatory health and social care might be conservative. Conversely, as some of this
care may have been provided as part of special schooling, there is also a risk of double counting care that is
bundled in with educational costs.
The decision analysis model is exploratory. The cost-effectiveness findings have a high degree of uncertainty
and include a number of strong underlying assumptions in interpolating and extrapolating some costs and
outcomes between birth, 10-year follow-up and age 18 years. A larger trial with more frequent follow-up
with parents and linkage to hospital and primary care records could reduce this uncertainty. Longitudinal
cohort studies estimating the impact of neurological impairment acquired at birth on long-term outcomes
and costs of care are also needed to determine the cost-effectiveness of interventions such as DRIFT over
the lifetime of the patient.
Comparison with other studies
The HUI3 scores we found in the DRIFT trial lie between the HUI3 scores reported among approximately
11-year-old children with moderate (mean HUI3 score of 0.744) and severe (mean HUI3 score of 0.364)
neurodevelopmental impairment following extremely preterm birth in the EPICure economic outcomes
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study.61 The EPICure economic outcomes study61 also found that mean health and social care costs in the
previous year were £1223 (at 2006/7 costs) among children with neurodevelopmental disability, increasing
to £8241 if educational costs were included. This, and our work, highlights the importance of taking a
broad perspective including cost of education in judging the cost-effectiveness of interventions in this
group of patients.
Our study can capture only a subset of the total economic consequences of childhood disability. In their
review of the literature, Stabile and Allin68 identify the broader spill-over effects on parental employment,
health and relationships as well as the long-term consequences for the child’s employment and need for
ongoing care and welfare benefits. They argue that many expensive interventions to prevent or reduce
childhood disabilities might well be justified if all these economic consequences can be taken into account.
The confidential inquiry into premature deaths of people with learning disabilities has highlighted the high
proportion of adults requiring residential or nursing home care and needing 24-hour care.19 However, as
other authors69 have noted, estimating the likely long-term return on investment of neonatal interventions
is severely hampered by the methodological variability in studies investigating the economic costs to
families who care for a child with disabilities.
Implications
The National Institute of Health and Care Excellence currently recommends that DRIFT should be used only
in the context of research. If DRIFT were implemented more widely in specialist NICUs, it would be relatively
straightforward to provide training to new teams in the NHS. One-to-one nurse staffing would need to be
factored in to provide the frequent monitoring required for DRIFT. We found that the intervention itself has
a relatively moderate financial cost, but the economic consequences of the procedure are potentially very
large, particularly if it reduces the need for special education in the long term. Our findings suggest that
DRIFT may increase cognitive status and reduce the need for special education at school age; however, more
evidence is required to determine whether or not the intervention is cost-effective. A larger multicentre RCT
with prospective economic evaluation would provide more definitive evidence. Economic modelling could
initially extrapolate the results of such a RCT; long-term follow-up would also be required.
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Chapter 5 Discussion and conclusions
Summary of findings
Infants who received DRIFT continued to demonstrate better cognitive ability at 10-year follow-up and
effects were significant when taking into account birthweight, IVH grade and gender (two of which were
unbalanced at baseline). The proportion of children who survived without severe cognitive disability was
significantly higher with DRIFT in both adjusted and unadjusted analyses. Children who received the DRIFT
intervention were nine times more likely to survive without severe cognitive disability and the NNT for
DRIFT to prevent one death or one case of severe cognitive disability was only three.
However, there were no apparent differences in the secondary outcomes: parent-reported visual
impairment, sensorimotor disability or emotional/behavioural difficulties.
High-resolution structural brain MRI at 10 years showed no evidence of residual damage associated with
insertion of the DRIFT irrigation catheters. A larger proportion of the standard treatment arm required
ventricular reservoirs and more residual frontal tracts associated with reservoirs were seen in the standard
treatment arm. There was no difference in ongoing neurosurgical problems between the treatment arms
at age 10 years.
Economic evaluation
Our findings suggest that DRIFT may increase cognitive status and reduce the need for special education at
school age; however, more evidence is required to determine whether or not the intervention is cost-effective.
Although the DRIFT intervention has a relatively moderate financial cost, the economic consequences of
the procedure are potentially very large, particularly if it continues to reduce the need for special education
in the long term.
Because of the high costs and likelihood of ongoing need of special education, the potential savings are
likely to be very influential in the economic case for DRIFT; it is likely to become more cost-effective over
the future lifetime of survivors. The exploratory decision analysis model to age 18 years indicated that
DRIFT has the potential to be cost-effective at conventional willingness-to-pay thresholds used by the NHS.
In some scenarios, DRIFT may save money and improve outcomes owing to the possible reduction in the
need for special education.
Strengths and limitations
The main strength of this study is the long-term follow-up to school age, which is more likely to give a
valid conclusion for future function and cognitive ability. Long-term follow-up of this nature is challenging
in neonatal clinical trials as families move around; it requires active buy-in from both parents and children
and a significant time commitment from families. In the case of conditions such as PHVD, a significant
proportion of survivors of which have severe neurodisabilities, the logistics and commitment around
returning for long-term assessments understandably become even more challenging.
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Precise cognitive assessment in children with a very wide range of abilities is a significant challenge for
trials. The approach to cognitive assessment in this study achieved a CQ in children of all abilities. Inclusion
of educational outcome as a pragmatic outcome was also important as this gives some idea of the likely
gains going forward into an independent adulthood.
Parent and family involvement and the organisation of the NHS ensured a very high follow-up rate at
school age in the UK. Only two patients had an unknown survival status at 10 years and, for this reason,
best- and worst-case scenarios were also explored.
The main limitation is the size of the trial and corresponding precision of the results. Given that this
intervention was innovative and the condition rare, the sample size, naturally, was conservative. The
intervention is invasive and, for safety insurance, the trial had stringent stopping criteria, which limited
the achieved sample size. Although the safety reasons for this are understandable and justifiable, it
unfortunately resulted in a smaller sample size than was required to give 80% power for the primary
outcome (CQ). Reassuringly, the binary outcome survival without severe cognitive disability was
significantly better in the DRIFT group both in adjusted and unadjusted analyses.
The majority of infants in the DRIFT trial and at 10-year follow-up were UK-based babies managed in
Bristol. The infants managed in Bristol were referred and transferred from all over the UK (33 hospitals in
total). Therefore, the UK trial cohort was probably representative of the wider UK population of preterm
infants with IVH and PHVD. The DRIFT trial also demonstrated that it is feasible to train highly motivated
teams in other centres to deliver the intervention within the context of a RCT. However, there remains
uncertainty around the extension of DRIFT trial results to new potential centres in the UK, which will need
to be resolved with further work on standardisation and training within the governance structure of a
UK-wide trial.
Owing to the modest size of this trial, the small numbers did result in imbalances in important
characteristics at baseline and, consequently, at 10-year follow-up. Infants in the DRIFT group were
significantly smaller, less mature and more likely to be male and had more severe-grade haemorrhages.
Therefore, prespecified adjustments were made in the primary, secondary and health economic analyses
using these covariates consistent with the earlier work.
Interpretation of results
DRIFT is the first intervention for PHVD in preterm infants to demonstrate benefit in a RCT. DRIFT also
demonstrates the proof of principle that washing away the debris of IVH in a controlled way reduces
secondary brain injury.
Rates of severe cognitive (learning) disability in the standard treatment arm were 52%, similar to previously
reported work5 in younger children with PHVD. The proportion of children with severe cognitive disability
was reduced with DRIFT to 21%. The CIPOLD study19 in England highlighted the complex lifelong health
and social care needs of individuals with significant learning disabilities; two-thirds of individuals lived in
residential care homes, the majority with 24-hour paid nursing care. Children who received DRIFT were
also more likely to attend mainstream schools. The reduction in severe cognitive disability seen with this
intervention is likely to translate into the ability to lead more independent lives into adulthood.
A multicentre RCT comparing two treatment thresholds for ventricular reservoir insertion after PHVD, the
Early vs. Late Ventricular Intervention Study (ELVIS; ISRCTN43171322), has recently ended recruitment.
Short-term outcomes should be published shortly but long-term neurological outcomes will not be known
before 2019.
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Newer interventions are also being tested. A feasibility and safety study of endoscopic ventricular lavage
showed fewer complications and need for VP shunts in larger (> 1000 g) preterm babies than standard
treatment in historical controls.29 However, as yet, neither short-term outcomes (complications and need
for shunts) nor long-term effects on neurological function have been reported in any controlled trial.
Implications for health care
The school-age follow-up of the DRIFT trial strengthens the evidence of benefit found at the 2-year follow-up
and adds further evidence of safety of the intervention. We conclude that DRIFT improves cognitive function
when taking into account birthweight, grade of IVH and gender. The cost of the intervention is moderate
and the reduction in the need for special education at school age is likely to translate into a cost-effective
intervention over a lifetime.
In the years since the DRIFT trial, neonatal intensive care organisation in the NHS has evolved into a highly
organised hub-and-spoke service mapped to large regions. Individual units in these operational delivery
networks (ODNs) are connected by dedicated neonatal transport services. Cases with PHVD could feasibly
be managed in this networked system by a small number of highly specialised units with neonatal
neurocritical care and neurosurgical expertise. Although the equipment and consumables used in DRIFT
are widely available, it needs to be acknowledged that DRIFT is potentially a high-risk intervention and
specialised units will need intensive neurosurgical, medical and nursing training in delivering DRIFT safely.
Future research implications
The demographics of the population of infants with PHVD has evolved since the DRIFT trial, with
significantly better survival in the 23- and 24-week gestation categories. A larger proportion of infants with
PHVD is now extremely immature, small and clinically unstable. Further refinements in DRIFT may need to
be studied in this very immature group of patients.
DRIFT has an effect on cognition but does not appear to improve motor function. The most likely explanation
is that simple irrigation, although effective at reducing secondary neurotoxicity and damage, is not sufficient
to promote tissue regeneration in critical motor pathways after significant parenchymal infarction. There is
scope to supplement DRIFT with novel interventions to promote brain tissue repair in the future.
The role of any NHS implementation of DRIFT, ideally in a few specialised tertiary centres, delivered
through the existing neonatal ODNs, will need to be studied prospectively in a multicentre trial. As well as
measures of cognition and functional measures, the data from the 10-year outcomes indicate that any
future studies should continue to collect data on vision, motor skills and education given the trends seen in
the secondary outcomes, which the study was not powered to address.
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Appendix 1 British Ability Scales version three,
school age
 
Patient ID
Raw Score  __________________________________
Raw Score __________________________________ 
Item Set 
Please select which pattern construction item set was used 
Std 
Alt 
Raw Score __________________________________
Item Set 
Item Set 1-14 
1-19 
5-19 
1-24 
5-24 
10-24 
5-29 
10-29 
15-29 
10-34 
15-34 
20-34 
15-38 
20-38 
1-13 1-17 5-17 1-21 5-21 5-27 14-27 14-33 22-33 
14-38 22-38 
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1-12  1-19  13-19  13-25  13-28  20-28  20-32  26-32  20-
35
26-35 
Raw Score __________________________________
Raw Score __________________________________
Item Set 
Raw Score __________________________________
Item Set 
Raw Score __________________________________
Item Set 
please select which pattern construction item 
set  
Item Set 
1-12 1-19 13-19 13-25 13-28 20-28 20-32 26-32 20-35 
26-35 26-38 
1-18 1-26 1-33 19-33 19-42 27-42 27-51 37-51 
1-12 1-20 8-20 8-27 15-27 15-32 21-32 15-37 21-37 
1-16 1-24 8-24 1-30 8-30 17-30 8-40 17-40 25-40 
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A 
B 
Raw Score 
Item Set 
__________________________________ 
 1-90  21-90  41-90  51-90 
Raw Score __________________________________ 
Item Set 
 1-90  21-90  41-90  51-90 
Recognition of Designs - Ability Score __________________________________ 
Recognition of Designs - T-score __________________________________ 
Recognition of Designs - Percentile __________________________________ 
Recognition of Designs - Difference from mean core T-score __________________________________ 
Recognition of Designs - Significance 
__________________________________ 
(p=0.05) 
Recognition of Designs - Significance (y/n)Yes No   
Recognition of Designs - Frequency (%) __________________________________ 
Recognition of Designs - Age Equivalent 
__________________________________ 
(yy:mm) 
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Word Definitions - Ability Score __________________________________ 
Word Definitions - T-score __________________________________ 
Word Definitions - Percentile __________________________________ 
Word Definitions - Difference from mean core T-score __________________________________ 
Word Definitions - Significance 
__________________________________ 
(p=0.05) 
Word Definitions - Significance (y/n) 
 
Word Definitions - Frequency (%) __________________________________ 
Word Definitions - Age Equivalent 
__________________________________ 
(yy:mm) 
Pattern Construction - Ability Score __________________________________ 
Pattern Construction - T-score __________________________________ 
Pattern Construction - Percentile __________________________________ 
Pattern Construction - Difference from mean core T-score __________________________________ 
Pattern Construction - Significance 
__________________________________ 
(p=0.05) 
Pattern Construction - Significance (y/n) 
Pattern Construction - Frequency (%) __________________________________ 
Pattern Construction - Age Equivalent 
__________________________________ 
(yy:mm) 
Matrices - Ability Score __________________________________ 
Matrices - T-score __________________________________ 
Matrices - Percentile __________________________________ 
Matrices - Difference from mean core T-score __________________________________ 
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Matrices - Significance 
__________________________________ 
(p=0.05) 
Matrices - Significance (y/n) 
Matrices - Frequency (%) __________________________________ 
Matrices - Age Equivalent 
__________________________________ 
(yy:mm) 
Verbal Similarities - Ability Score __________________________________ 
Verbal Similarities - T-score __________________________________ 
Verbal Similarities - Percentile __________________________________ 
Verbal Similarities - Difference from mean core T-
score 
__________________________________ 
Verbal Similarities - Significance 
__________________________________ 
(p=0.05) 
Verbal Similarities - Significance (y/n) 
Verbal Similarities - Frequency (%) __________________________________ 
Verbal Similarities - Age Equivalent 
__________________________________ 
(yy:mm) 
Quantitative Reasoning - Ability Score __________________________________ 
Quantitative Reasoning - T-score __________________________________ 
Quantitative Reasoning - Percentile __________________________________ 
Quantitative Reasoning - Difference from mean core T-score __________________________________ 
Quantitative Reasoning - Significance 
__________________________________ 
(p=0.05) 
Quantitative Reasoning - Significance (y/n) 
Quantitative Reasoning - Frequency (%) __________________________________ 
Quantitative Reasoning - Age Equivalent 
__________________________________ 
(yy:mm) 
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 Mean T-score 
__________________________________ 
Word Reading - Ability Score __________________________________ 
Word Reading - Standard Score __________________________________ 
Word Reading - Percentile __________________________________ 
Word Reading - Difference from GCA score __________________________________ 
Word Reading - Significance 
__________________________________ 
(p=0.05) 
Word Reading - Significance (y/n) 
Word Reading - Frequency (%) __________________________________ 
Word Reading - Age Equivalent 
__________________________________ 
(yy:mm) 
 
Verbal Ability - Word Definitions __________________________________ 
Verbal Ability - Verbal Similarities __________________________________ 
Non-Verbal Reasoning Ability - Matrices __________________________________ 
Non-Verbal Reasoning Ability - Quantitative Reasoning __________________________________ 
Spatial Ability - Recognition of Designs  __________________________________ 
Spatial Ability - Pattern Construction __________________________________ 
 
Verbal Ability T-Scores __________________________________ 
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Non-Verbal Reasoning Ability T-score __________________________________ 
Spatial Ability- T-score __________________________________ 
Sum of T-Scores __________________________________ 
SNC - Sum of T-scores __________________________________ 
Verbal Ability - Standard Score __________________________________ 
Verbal Ability - Confidence Interval __________________________________ 
(-95%) 
Verbal Ability - Percentile __________________________________ 
Non-Verbal Reasoning Ability - Confidence Interval __________________________________ 
(-95%) 
Non-Verbal Reasoning Ability - Standard Score __________________________________ 
Non-Verbal Reasoning Ability - Percentile __________________________________ 
Spatial Ability - Standard Score __________________________________ 
Spatial Ability - Confidence Interval __________________________________ 
(-95%) 
Spatial Ability - Percentile __________________________________ 
GCA - Standard Score __________________________________ 
GCA - Confidence Interval __________________________________ 
(-95%) 
GCA - Percentile __________________________________ 
SNC - Standard Score __________________________________ 
SNC - Confidence Interval __________________________________ 
(95%) 
SNC - Percentile __________________________________ 
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Appendix 2 British Ability Scales version three,
early years
 
  
Patient ID 
__________________________________ 
Raw Score    __________________________________ 
Item Set
 
Raw Score __________________________________
Item Set
 
Raw Score __________________________________
Item Set
'1-12 '1-23 '6-23 '6-30 '13-30 '13-40 '13-23/31-40
'1-23 '1-28 '12-28 '12-35 '19-35 
1-17 1-24 11-24 1-31 11-31 18-31 11-36 18-36
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Please select which pattern construction item set was used 
Std 
Alt 
 
Raw Score__________________________________ 
Item Set 
1-12  1-19  13-19  13-25  13-28  20-28  20-32  26-32  20-
35      26-35 
 
Raw Score___________________________
 
Raw Score__________________________________ 
Item Set
 
Raw Score__________________________________ 
Item Set 
1-12 1-19 13-19 13-25 13-28 20-28 20-32 26-32 20-35 
26-35 26-38 
1-18 1-26 1-33 19-33 19-42 27-42 27-51 37-51 
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Item Set
 
Verbal Comprehension - Significance (y/n)Yes No    
Verbal Comprehension - Frequency (%) __________________________________ 
Verbal Comprehension - Age Equivalent __________________________________ 
(yy:mm) 
Verbal Comprehension - Ability Score __________________________________ 
Verbal Comprehension - T-score __________________________________ 
Verbal Comprehension - Percentile __________________________________ 
Verbal Comprehension - Difference from mean core T-
score 
__________________________________ 
Verbal Comprehension - Significance 
__________________________________ 
(p=0.05) 
1-12 1-15 5-15 1-20 5-20 11-20
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Picture Similarities - Significance __________________________________ 
(p=0.05) 
Picture Similarities - Significance (y/n)Yes No 
Picture Similarities - Frequency (%) __________________________________ 
Picture Similarities - Age Equivalent 
__________________________________ 
(yy:mm) 
Naming Vocabulary - Ability Score __________________________________ 
Naming Vocabulary - T-score __________________________________ 
Naming Vocabulary - Percentile __________________________________ 
Naming Vocabulary - Difference from mean core T-score __________________________________ 
Naming Vocabulary - Significance 
__________________________________ 
(p=0.05) 
Naming Vocabulary - Significance (y/n) 
Naming Vocabulary - Frequency (%) __________________________________ 
Naming Vocabulary - Age Equivalent 
__________________________________ 
(yy:mm) 
Picture Similarities - Ability Score __________________________________ 
Picture Similarities - T-score __________________________________ 
Picture Similarities - Percentile __________________________________ 
Picture Similarities - Difference from mean core T-
score 
__________________________________ 
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Pattern Construction - Ability Score __________________________________ 
Pattern Construction - T-score __________________________________ 
Pattern Construction - Percentile __________________________________ 
Pattern Construction - Difference from mean core T-score __________________________________ 
Pattern Construction - Significance 
__________________________________ 
(p=0.05) 
Pattern Construction - Significance (y/n) 
Matrices - Ability Score __________________________________ 
Matrices - T-score __________________________________ 
Matrices - Percentile __________________________________ 
Matrices - Difference from mean core T-score __________________________________ 
Matrices - Significance 
__________________________________ 
(p=0.05) 
Matrices - Significance (y/n) 
Matrices - Frequency (%) __________________________________ 
Matrices - Age Equivalent 
__________________________________ 
(yy:mm) 
Copying - Ability Score __________________________________ 
Copying - T-score __________________________________ 
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Copying - Percentile __________________________________ 
Copying - Difference from mean core T-score __________________________________ 
Copying - Significance 
__________________________________ 
(p=0.05) 
Copying - Significance (y/n) 
Copying - Frequency (%) __________________________________ 
Copying - Age Equivalent 
__________________________________ 
(yy:mm) 
Mean T-score __________________________________ 
 
Verbal Ability - Verbal Comprehension __________________________________ 
Non-verbal reasoning ability - Picture Similarities __________________________________ 
Verbal Ability- Naming Vocabulary __________________________________ 
Spatial Ability - Pattern Construction __________________________________ 
Non-Verbal Reasoning Ability- Matrices __________________________________ 
Spatial Ability - Copying __________________________________ 
 
Verbal Ability T-Scores __________________________________ 
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Non-Verbal Reasoning Ability T-score __________________________________ 
Spatial Ability T-score __________________________________ 
Sum of T-Scores __________________________________ 
SNC - Sum of T-scores __________________________________ 
Verbal Ability - Standard Score __________________________________ 
Verbal Ability - Confidence Interval __________________________________ 
(-95%) 
Verbal Ability - Percentile __________________________________ 
Non-Verbal Reasoning Ability - Confidence Interval __________________________________ 
(-95%) 
Non-Verbal Reasoning Ability - Standard Score __________________________________ 
Non-Verbal Reasoning Ability - Percentile __________________________________ 
Spatial Ability - Standard Score __________________________________ 
Spatial Ability - Confidence Interval __________________________________ 
(-95%) 
Spatial Ability - Percentile __________________________________ 
GCA - Standard Score __________________________________ 
GCA - Confidence Interval __________________________________ 
(-95%) 
GCA - Percentile __________________________________ 
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SNC - Standard Score __________________________________ 
 
SNC - Confidence Interval __________________________________ 
(95%) 
SNC - Percentile __________________________________ 
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Appendix 3 Bayley Scales of Infant and Toddler
Development version three
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Appendix 4 Visual questionnaire
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Appendix 5 Movement Assessment Battery for
Children-2
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Appendix 6 Strengths and Difficulties
Questionnaire
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